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ABSTRACT 
Laura A. Smith: Impact of Advanced Age and Dietary Energy Balance on Mammary 
Tumor Progression and the Tumor Microenvironment 
(Under the direction of Stephen Hursting) 
Advanced age and obesity are two major risk factors for breast cancer (BC) 
mortality, which presents significant public health concern for our aging population and 
its increasing burden of obesity. Research into mechanisms underlying the obesity-BC 
link has identified obesity-associated mammary adipose inflammation and tumor 
immunosuppression as major contributors to enhanced mammary tumor growth. In 
contrast, the impact of advanced age on BC remains poorly understood. In Chapter 1 
we sought to determine if advanced age accelerates mammary tumor growth and, 
following our observation that it did, investigate if shared mechanisms drive advanced 
age- and obesity-associated mammary tumor burden. Accelerated tumor growth in 
advanced aged and diet-induced obesity (DIO) mice, compared with young 
normoweight mice, was associated with convergent transcriptional patterns indicative of 
mammary adipose inflammation and tumor immunosuppression. In addition, aged and 
DIO mice, compared with young normoweight mice, had reduced tumoral abundance of 
CD8 T cells, or cytotoxic immune cells that constrain mammary tumor growth in our BC 
models, and diminished transcription for genes encoding cytotoxic effector molecules. 
These data indicate that advanced age and obesity promote acquisition of an inflamed, 
immunosuppressive tumor-adjacent mammary adipose and an immunosuppressed 
mammary tumor microenvironment which contribute to mammary tumor growth.  
iv 
We subsequently tested efficacy of various dietary interventions in reversing 
obesity- and advanced age-associated increased tumor burden and 
immunosuppression. In young DIO mice, chronic calorie restriction (CCR) and 
intermittent calorie restriction (ICR), however not low-fat diet, attenuated tumor growth 
and reversed DIO-associated tumor immunosuppression. Given CCR and ICR provided 
comparable benefit in young DIO mice, we tested if ICR offered similar benefit to aged 
and aged DIO mice. Compared with ad libitum-fed comparators, ICR in young DIO, 
aged, and aged DIO mice reduced mammary tumor growth and enhanced tumoral 
transcripton of immune-related signatures. Thus, weight loss by calorie restriction 
interventions reverses advanced age- and obesity-associated increases in mammary 
tumor growth and tumor immunosuppression.  Implementation of low-cost dietary 
interventions for cancer prevention and treatment would have far reaching public health 
impacts; however, more work is needed to determine feasibility of interventions in BC 
patients that are aged, obese, or aged and obese. 
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CHAPTER 1. BACKGROUND  
Breast Cancer (BC): A Public Health Concern in the United States (US) and World-
Wide 
Breast cancer is the most diagnosed noncutaneous cancer among women in the 
US, and although current treatment paradigms provide relatively good survival, BC has 
the second highest mortality rate of all cancers in US women1. It is estimated that BC 
will take the lives of 40,000+ US women this year, accounting for 15% of all cancer-
related deaths.2 The burden of BC is also observed globally, being the most diagnosed 
(~25% of all new cancer cases) and deadliest cancer (~15% of all cancer-related 
deaths) among women worldwide3.  
Distinct molecular subtypes of BC have been identified based on gene 
expression profiling (i.e. luminal A, luminal B, HER2-enriched, basal-like, and claudin-
low)4,5. These subtypes predict therapeutic responses and disease prognosis6. This 
dissertation project utilizes preclinical models of claudin-low and basal-like BC, 
subtypes associated with poorer prognoses7-9. Distinguishing features of claudin-low 
tumors are low gene expression levels of tight junction proteins claudin 3, 4 and 7 and 
E-cadherin6,7. Claudin-low tumors show reduced relapse-free and overall-survival, 
compared with luminal A subtype7,8,10. In addition, claudin-low tumors exhibit significant 
immune infiltration and high expression of genes related to epithelial-to-mesenchymal 
transition, a process implicated in BC progression to metastasis7,10. Basal-like BC is 
defined by high expression of cytokeratins (e.g. CK5/6) and epidermal growth factor 
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receptor, and often lacks estrogen receptor, progesterone receptor, and amplification of 
the human epidermal growth factor receptor-24. Similar to claudin-low tumors, basal-like 
tumors have increased immune infiltrate and are associated with shorter disease-free 
and overall survival9,11.  
Obesity and Advanced Age Negatively Influence BC Outcomes 
According to the World Health Organization, approximately 13% of adults 
worldwide were obese in 2016, as defined by a body mass index of 30 kg/m2 or greater, 
which reflects a tripling of the obesity rate since 197512. The US is disproportionately 
affected by obesity as an alarming 42.4% of adults were classified as obese between 
2017-201813. Obesity increases a woman’s risk of BC development, predominantly in 
postmenopausal women, and confers worse disease outcomes, including greater 
mortality and shorter time to disease recurrence, in both premenopausal and 
postmenopausal patients with BC14,15. Research from our lab, as well as others, 
demonstrates that obesity-associated increases in BC incidence and progression is 
recapitulated in preclinical models16-20. Our lab utilizes models of diet-induced obesity 
(DIO) in which mice are placed on a high-fat (60% kcal from fat) DIO regimen prior to 
tumor inoculation. DIO-feeding significantly increases mouse body weight and body fat 
mass and alters profiles of serum metabolites (e.g. leptin and insulin), growth factors 
(e.g. insulin-like growth factor-1 (IGF-1)), and inflammatory mediators (e.g. interleukin 
(IL)-6 and tumor necrosis factor alpha (TNFα)), consistent with observations in obese 
humans18,21,22. Using our models of claudin-low and basal-like BC, we have 
demonstrated that DIO-feeding increases primary tumor growth and lung metastasis, 
compared with normoweight control mice17-20. Increasing prevalence of obesity in our 
populations combined with obesity-associated increases in BC risk has spurred 
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extensive investigation into underlying mechanisms, including adipose inflammation and 
immune dysfunction, which will be described later in this chapter. 
Advanced age is another strong risk factor for BC incidence and mortality which 
signifies a critical public health concern due to aging of the US and global 
populations11,12,23. The world’s population is trending upward in age, and the proportion 
of individuals over the age of 65 globally is projected to increase from 9% in 2019 to 
16% by 205023.  Relative to other regions of the world, elderly individuals are more 
prevalent in Europe and North America, wherein 18% of these populations in 2019 were 
aged 65 and older and this rate is projected to increase to 26% of these populations by 
205023.  
The increasing proportion of women aged 65 years or older is concerning from a 
cancer perspective as 45% of BC diagnoses and 60% of BC-related deaths occur in 
women aged 65 years or older24,25. Further, advanced age at diagnosis is associated 
with increased BC-specific mortality in many studies; however, few indicate no 
difference in BC survival with advanced age (Table 1.1)26-31. One large retrospective 
cohort study tested the effects of age on BC-specific mortality using Surveillance, 
Epidemiology and End Results-Medicare data collected on 49,616 women aged 67 or 
older30. They found that women aged 80-84, 85-89, and ≥90 diagnosed with either 
Stage I or Stage II BC had significantly increased risk of dying from BC compared with 
patients 67-69 years of age30. Another smaller study showed that patients greater than 
80 years of age have increased BC-specific mortality at 5 and 10 years following 
diagnosis, compared with patients aged 40-49 years26. In contrast, one study found no 
significant difference in BC-specific mortality in patients 70-79 and greater than 80 years 
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of age compared with patients 40-49 years old31, while another report found that 
advanced age was associated with reduction in overall survival but not BC-specific 
survival28. Discrepancies across these findings may be explained by advanced age 
exerting differential effects on BC outcome based on BC subtype. Among patients with 
hormone receptor negative and triple negative BC, which are subtypes lacking targeted 
therapy and associated with aggressive disease, advanced age predicted decreased 
BC-specific survival27,29. Larger randomized clinical trials are warranted to discern the 
impact of advanced age on patient survival across all BC subtypes. In the meantime, 
preclinical studies can be utilized to elucidate the consequences of advanced age-
related biology on BC growth and progression.  
Few preclinical studies have investigated the effects of age on BC growth. One  
study examined whether older (12 months), versus younger (8-10 weeks), mice 
exhibited differential growth kinetics across multiple mammary carcinoma models32. At 
early timepoints, 4T1 mammary tumors were significantly larger in older mice; however, 
these differences were ameliorated by endpoint producing no significant difference in 
tumor size compared with younger mice32. On the other hand, Met1 tumors grew more 
slowly in older mice, producing significantly smaller tumors compared with younger mice 
at 30 days post tumor inoculation32. Further investigation utilizing three different 
mammary tumor cell lines confirmed strain-specific differences with 4T07 and 67NR 
cells  having similar growth and McNeuA cells having slower growth in older compared 
with younger mice32.  In a second study, authors found that 4T1 mammary carcinoma 
cells grew more slowly in 12-15-month-old mice compared with 2-3-month-old mice33. 
Similarly, a third study found decreased tumor growth in aged mice (>10 months), 
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relative to young mice (8-10 weeks), following transplantation with tumor cells that 
model triple-negative (BPLER) and luminal (MCF7Ras) BC subtypes34. The average 
lifespan of a laboratory mouse is (approximately 23-32 months)35; therefore, these 
studies compared mammary tumor growth in mice halfway through their lifespan (10-15 
months old) versus 3-month-old mice, an age just after maturation that is typically used 
in preclinical BC studies. To better assess the effects of advanced age on BC growth, 
this dissertation work utilized 17-18-month-old female C57BL/6J mice, which are 
approximately two-thirds through their average lifespan35,36. As a “young” comparator, 
7-8-month-old mice were used as mice of this age are considered adult yet lack 
biomarkers of aging such as elevated p16 expression37. 
Increasing prevalence of obesity and advanced age in our population combined 
with age- and obesity-associated increases in BC risk highlights the need to understand 
the mechanistic contributions of obesity and advanced age to BC progression. In the 
next section the tumor immune microenvironment and mechanisms through which a 
tumor evades immune elimination are described. Following, the roles of obesity-related 
adipose inflammation and immune dysfunction in promoting tumor immunosuppression 
are discussed, then parallels are drawn between obesity-associated versus age-related 
adipose inflammation and immune dysfunction. 
Tumor Immune Microenvironment 
Cancer cells acquire genetic changes that lead to the expression of neoantigens, 
or peptides derived from mutated proteins, that in turn can be recognized by the host 
immune system and elicit an antitumor immune response38. Other tumor antigens, 
including tissue differentiation antigens or oncoviral antigens, can be recognized by the 
immune system; however, associations drawn between tumor mutational landscape and 
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response to immune modulatory immunotherapy suggest that neoantigens are critical 
for tumor immunogenicity39,40. Successful antitumor immunity requires a series of 
carefully orchestrated interactions between cancer cells and different immune cells41. 
First, tumor-specific antigens must be present on the cancer cell surface, bound to 
major histocompatibility class I (MHCI), or released from a dying tumor cell.  These 
tumor-specific antigens are captured and processed by dendritic cells, complexed with 
MHCI or MHCII molecules, and presented to CD8 and CD4 T cells. This antigen 
presentation results in T cell priming and activation of effector responses against the 
cancer-specific antigen. Next, these activated effector T cells must traffic to the tumor 
and infiltrate the tumor bed. Chemokines, including CXCL9 and CXCL10, promote T cell 
recruitment to the tumor bed, and adhesion molecules, facilitate T cell infiltration into the 
tumor tissue42,43. Once in the tumor microenvironment, effector T cells recognize tumor-
specific antigens and bind to the associated cancer cell via interaction between the T 
cell receptor and MHCI containing the cognate antigen. T cells then execute their 
cytotoxic effector functions to kill the target T cell41. These functions include release of 
perforins, which forms transmembrane pores in the target cell, and granzymes, which 
pass through perforin pores and induce cell death44. Following this immune-mediated 
cancer cell death, cancer-specific antigens are released into the tumor 
microenvironment which initiates an antitumor immune response, increasing the extent 
of the response41. 
While the antitumor immune response is intended to kill and clear cancerous 
cells, persistent activation of the immune system due to unresolved disease manifests 
in immunoregulatory mechanisms to limit collateral damage to healthy tissues45. 
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Mechanisms deployed to constrain immunopathology include upregulation of inhibitory 
immune checkpoint molecules (e.g. programmed cell death protein 1 (PD-1) and 
programmed death-ligand 1 (PD-L1)), activation of immunosuppressive cells (e.g. T 
regulatory cells and tumor associated macrophages), and release of 
immunosuppressive cytokines (e.g. IL-10)45. Ultimately, these actions inhibit 
functionality of cytotoxic T cells that are critical in successful antitumor immunity41. 
Furthermore, cancer cells that escape immune elimination become less immunogenic, 
by downregulating MHC molecules, and actively promote immunosuppression by 
secreting and upregulating expression of immune modulatory factors that suppress T 
cell responses.  
Multiple mechanisms that limit the ability of cytotoxic T cells to generate and 
execute antitumor immune function include subversion of T cell priming, inhibition of T 
cell infiltration, and suppression of T cell function45. Priming of T cells occurs early in the 
antitumor immune response when an antigen-presenting cell presents a tumor-specific 
antigen to a naïve CD8 T cell41. Upon presentation, three specific interactions must 
occur for optimal priming: 1) the T cell receptor with MHCI receptor complexed with 
tumor-specific antigen, 2) T cell co-stimulatory receptor with appropriate ligand (e.g. 
CD28 with CD80 or CD86), and 3) appropriate inflammatory cytokine (e.g. IL-12 or 
interferon ) with their respective receptor45,46. Suboptimal priming can occur due to 
reduced abundance or dysfunction of dendritic cells locally within the tumor or 
systemically47. In support, greater abundance of dendritic cell-related transcription within 
human tumors is correlated with increased overall survival in breast cancer patients48. 
Macrophages are another type of antigen-presenting cell that is often more abundant in 
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the tumor microenvironment than dendritic cells; however, tumor-associated 
macrophages develop a distinct phenotype, compared with macrophages in healthy 
tissues, that is characterized by poorer antigen-presentation capabilities and the 
production of factors that suppress T cell functions49. Specifically, secretion of IL-10 
from tumor-associated macrophages can suppress dendritic cell production of IL-12 and 
subsequently the priming and activity of cytotoxic T cells50. Additionally, aberrant lipid 
metabolism and accumulation of lipid in dendritic cells can impair their ability to process 
and present antigen to T cells51. Moreover, tumors can lose neoantigen expression 
through elimination of tumor subclones expressing the antigen or deletion of 
chromosomal regions that encode the antigen52. 
Even if cytotoxic T cells are optimally primed against cancer-specific antigens, 
they can fail to infiltrate the tumor bed, which impedes their ability to interact with and 
kill cancerous cells. T cell exclusion from tumors is observed in multiple types of cancer 
including breast cancer, and is associated with poor prognosis in patients53-56. In the 
context of breast cancer, the prognostic value of CD8 T cell infiltration may be different 
across subtypes. Two studies demonstrate that CD8 T cell infiltration is only associated 
with favorable prognosis in estrogen receptor negative or basal-like subtypes57,58. 
Mechanisms influencing T cell infiltration into tumors include chemokine expression and 
vasculature perturbations. 
Secreted by tumor cells, immune cells, or other stromal cells, chemokines are 
signaling proteins that regulate the immune cell recruitment to the tumor. Numerous 
chemokines have been associated with increased tumor-infiltration by T cells including 
CCL2, CCL3, CCL4, CCL5, CXCL9, CXCL10, and CXCL1159. CXCL9 and CXCL10 
 
9 
recruit memory CD8 T cells expressing their receptor CXCR3 and are associated with 
Th1 immune responses60. Further, CXCR3 signaling aids in migration of T cells from the 
vasculature into the tumor bed61. Vascular perturbations that inhibit T cell infiltration 
include 1) downregulated expression of intracellular adhesion molecule 1 (ICAM-1) cell 
surface receptor that mediates vasculature interaction with leukocytes, 2) upregulation 
of Fas ligand that induces apoptosis in Fas-expressing CD8 T cells, and 3) upregulation 
expression of T cell inhibitory receptors (e.g. PD-L1) and secretion of inhibitory 
molecules (e.g. IL-6)60. 
Once in the tumor microenvironment, T cells face further challenge. Tumor cells 
can upregulate expression of inhibitory receptors (e.g. PD-L1) and secrete suppressive 
molecules (e.g. IL-10, transforming growth factor beta (TGFβ), and prostaglandin E2 
(PGE2)) that directly block T cell function62-64.  The tumor-derived suppressive factors 
can also recruit immunosuppressive immune cells (e.g. regulatory T cells, tumor 
associated macrophages, or myeloid derived suppressor cells)60. In addition, chronic 
antigen exposure without resolution of the tumor can lead to upregulation of inhibitory 
receptors on T cells, including PD-1 and cytotoxic T-lymphocyte-associated protein 4 
(CTLA-4), that control the extent and quality of the cell’s response when engaged with 
their respective ligands60. Finally, tumors utilize aerobic glycolysis, even when sufficient 
oxygen, to meet high energy demand and provide synthetic materials to support 
continued growth65,66. This creates a nutrient scarce, hypoxic environment unfavorable 
for T cell survival and function60. Thus, multiple host and tumor factors can inhibit the 




 Clinically, the tumor immune microenvironment (TIME) is classified based on the 
composition of the immune cell infiltrate and expression of factors related to the 
inflammatory response, to be either infiltrated-excluded, infiltrated-inflamed, or 
infiltrated-tertiary lymphoid structures67.  Infiltrated-excluded TIMEs exhibit exclusion of 
cytotoxic lymphocytes from the tumor core and reduced expression of cytotoxic effector 
molecules (e.g. granzyme B and interferon gamma (IFN-g))67. Features of the infiltrated-
excluded TIMEs suggest immunological ignorance or inability of the adaptive immunity 
to recognize tumor antigen and invoke an antitumor immune response. In contrast, 
infiltrated-inflamed TIMEs contain highly activated cytotoxic lymphocytes expressing 
effector molecules (e.g. granzyme B and IFN-g) as well as checkpoint molecules (e.g. 
PD-1)67. Finally, infiltrated-tertiary lymphoid structure TIMEs contain ectopic lymphoid 
components with cellular composition analogous to that observed in lymph nodes (e.g. 
naïve and activated conventional T cells, T regulatory cells, and dendritic cells)67. In the 
context of BC, tumors that exhibit infiltrated-inflamed features (e.g. increased total 
lymphocyte infiltration and/or CD8+ lymphocyte infiltration) predict of more favorable 
patient survival57,58.  
Obesity-Associated Adipose Inflammation and Immune Dysfunction Drive BC 
Progression and Promote Tumor Immunosuppression 
Obesity facilitates BC progression through propagation of inflammation within the 
tumor-adjacent mammary microenvironment and cultivation of an immunosuppressed 
tumor microenvironment68. Our lab and others have demonstrated that preclinical 
mouse models of obesity increase BC progression, a phenomenon consistent with 
epidemiological findings17,18. Utilization of these preclinical models have allowed 
investigation into the mechanistic underpinnings of this relationship. Obesity often leads 
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to inflammatory changes within the adipose tissue, including increased expression of 
proinflammatory mediators that cultivates a state of low-grade, chronic inflammation68,69. 
These proinflammatory cytokines (e.g. TNFα, IL-6) enhance cancer progression both 
directly, promoting cancer cell proliferation, and indirectly, inducing tumor supportive 
alterations within the environment such as fibrosis and angiogenesis. Obesity-
associated inflammation also coincides with an altered immune landscape.  Specifically, 
expansion of adipose tissue in response to overnutrition increases adipocyte 
dysfunction and death as well as release of cytokines, chemokines and cellular contents 
into the surrounding tissue68. In response, classically activated macrophages and 
monocytes surround these adipocytes to form “crown-like structures70. Multiple 
inflammation-related pathways are thus triggered, including: i) NOD-like receptor signals 
in response to release of damage-associated molecular proteins;  ii) Toll-like receptors 
in response to free fatty acids; and iii) NF-κB signaling in response to cytokines and 
chemokines that facilitate the recruitment and activation of proinflammatory immune 
cells68,71. Elevated leptin secretion from adipocytes and associated signaling, which is 
also elevated in obesity, elicits the production of inflammatory cytokines72, and directs 
immune cells towards proinflammatory phenotypes such as Th1 CD4 T cells and M1 
macrophages69,72. Moreover, obese adipose tissue exhibits elevated expression of IFN-
g, a major immunomodulatory cytokine that orchestrates host immune responses, 
further perpetuating the proinflammatory milieu73,74. Durative activation of CD8 T cells 
leads to increased expression of inhibitory receptors and suppression of T cell effector 
functions, resulting in dysfunctional T cell phenotypes75,76. Obesity increases the 
frequency of dysfunctional T cells within adipose tissue, including senescent77 and 
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exhausted phenotypes78, and reduces T cell responsiveness to viral atigens79. 
Ultimately, obesity-associated inflammation provokes a pivot in the adipose T cell 
repertoire towards proinflammatory, exhausted and/or dysfunctional CD8, Th1 CD4, and 
Th17 CD4 T cells, as well as downregulated anti-inflammatory Th2 CD4 T cells and 
regulatory T cells68,80.  
While the majority of the work described above has been conducted in the 
context of the visceral adipose tissue, studies have shown obesity-associated 
inflammation to extend into the subcutaneous mammary adipose, the host 
microenvironment in which BC cells grow. Specifically, DIO increases presence of 
crown-like structures and elevates expression of inflammatory-related genes within the 
mammary adipose17. In agreement, clinical data indicates that overweight and obese 
patients with early-stage BC exhibit increased inflammation in normal breast adipose, 
as evidenced by presence of crown-like structures and activation of NF-κB, a 
transcription factor that stimulates the expression of proinflammatory genes81.  
Independent of adiposity, increased crown-like structures in breast adipose is 
associated with poorer survival in BC patients82.  
The chronic state of inflammation observed in obesity and the resultant 
modulation of immune cell populations ultimately impairs antitumor immune responses 
and reshapes the tumor immune microenvironment. Tumor-infiltrating cytotoxic CD8 T 
cells in obese mice exhibit “exhausted” characteristics, including decreased expression 
of proliferation marker Ki67, reduced transcription of cytotoxic effectors (e.g. granzyme 
B), and increased expression of inhibitory checkpoint molecules (i.e. PD-1, Tim3, and 
Lag3), compared with lean mice78,83. Obesity also increases abundance of T cell 
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suppressive immune cells including myeloid-derived suppressor cells that express PD-
L1, the ligand for PD-1 that diminishes T cell activation upon ligation84. In addition to 
these tumor immune aberrations, obesity was associated with increased tumor growth 
in these studies. Thus, obesity cultivates immunosuppression within the tumor 
microenvironment that facilitates increased tumor burden. 
Advanced Age Parallels Adipose Inflammation and Immune Dysfunction 
Observed In Obesity 
Similar to obesity, advanced age induces chronic, low grade inflammation and 
immune dysfunction both systemically and within the adipose tissue, often referred to as 
“inflammaging”85. A major contributor to age-related chronic inflammation is cellular 
senescence, or stress-induced cell cycle arrest86. Senescent cells accumulate with 
advanced age and adapt a senescence-associated secretory phenotype (SASP) which 
includes a variety of proinflammatory mediators (e.g. IL-1β, IL-6, and PGE2) that 
maintain a low-grade adaptive immune response87. Simultaneously, advancing age 
results in immunosenescence, or age-related immune dysfunction, largely characterized 
by a reduction in naïve T cells, shrinking in the T cell receptor repertoire, and increased 
memory T cells88. Specific to adipose tissue, advanced age-related alterations to the 
immune landscape converge with that observed in obesity85, including increased 
infiltration of CD8+ T cells89, increased frequency of senescent and exhausted T cell 
phenotypes90, and shifting of macrophage populations towards proinflammatory M1 
phenotypes85,89, Again, the majority of these findings are within the context of the 
visceral adipose tissue and age-related effects on the subcutaneous mammary adipose 
are unexplored.  More recently, investigation into the mammary tumor 
microenvironment from aged mice demonstrates reduced immune-related signaling and 
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decreased frequency of tumor-infiltrating CD8 T cells expressing immune modulatory 
IFN-g compared With Younger Mice32.  
Dietary Interventions Exert Opposing Effects by Reducing Inflammation, 
Improving Immune Function, and Attenuating BC Progression 
Given enhanced BC burden faced by patients with advanced age and obesity, 
interventions are urgently needed to break the advanced age-BC and obesity-BC links 
and improve outcomes in these high-risk patient populations.  Dietary interventions 
represent promising strategies that would be low-cost and highly accessible to patients 
and have been associated with reduced inflammation and tumorigenesis. Numerous 
types of dietary interventions are utilized in clinical trials including chronic calorie 
restriction (CCR), intermittent fasting (IF), and low-fat (LF) diet. Preclinical and some 
clinical studies suggest that CCR, IF, and LF interventions can favorably and inversely 
modulate cancer risk biomarkers including markers of inflammation, attenuate 
tumorigenesis, and, in regard to CCR and IF, improve immune function, as discussed 
below.  
Calorie restriction 
Calorie restriction, defined as reduction of dietary energy intake without 
malnutrition, is broadly effective dietary intervention that significantly decreases 
adiposity. Preclinical models demonstrate that 30% chronic CR (CCR), compared with 
ad libitum-fed control, ameliorates risk factors and delays onset of cancer through 
metabolic alterations fostering increased insulin sensitivity and decreased serum 
glucose, serum triglycerides, growth factor signaling, inflammation, oxidative stress and 
angiogenesis91-95. These metabolic changes translate into significantly decreased 
cancer incidence in murine models96. Specific to BC, CCR reduces incidence, increases 
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latency, and slows growth of mammary tumors in lean mice22,95,97. Further, CCR 
improves tumor immune surveillance, increasing abundance of CD8 T cells relative to 
myeloid derived suppressor cells within the mammary tumor microenvrionment98. CCR 
in obese mice reduces expression of inflammatory cytokines systemically and within the 
mammary gland, reverses obesity-associated increases in adipose infiltrating CD8 and 
CD4 T cells and macrophages, and attenuates mammary tumor growth (Bowers et al. 
Unpublished)99-101.  
Due to long latency of cancer in humans, the literature does not have data linking 
CCR directly with cancer incidence in humans. However, randomized control trials 
implementing long-term 20% CCR in overweight human subjects have confirmed 
reduced adiposity and improved levels of BC risk biomarkers (e.g. reduce circulating 
glucose, leptin, and inflammatory markers TNFa and C-reactive protein)102,103. 
Substantial weight loss of >10% may be necessary to consistently observe these 
benefits104-106.  
Further, CCR improves immune function in aged or obese animals and humans. 
CCR attenuates age-related declines in immune function by increasing naïve CD8 and 
CD4 T cell populations and TCR diversity in nonhuman primates, compared with ad 
libitum-fed controls107. In addition, enhanced CD4 T-cell priming and antigen-specific 
responses were observed in aged CCR mice, compared with aged ad libitum-fed mice, 
following treatment with αOX40, agonist for OX40 T cell co-stimulatory receptor108. In 
obese mice, CCR reverses obesity-associated increases in adipose infiltrating CD8 and 
CD4 T cells and macrophages. In obese humans, CCR increases mitogen-stimulated 
lymphocyte proliferation and reduces production of PGE2, a T cell suppressive factor109.  
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Direct application of CCR in cancer patients is complicated by high rates of 
weight loss associated with cancer cachexia, a condition in which tumor-derived signals 
degrade muscle and adipose tissue. A recent trial combining CCR and physical activity 
suggests presurgical weight loss is safe and feasible in prostate cancer patients.110 
Moreover, preliminary clinical trials suggest that application of CCR in combination with 
chemotherapy and/or radiation has potential to reduce risk biomarkers and increase 
responsiveness to treatment111,112.  
Intermittent fasting  
Preclinical and clinical studies have begun to explore implementation of 
intermittent fasting (IF), which may be easier for some patients to adopt than chronic 
restriction. Human trials most often study one of three IF regimens: alternate day 
fasting, alternate day calorie restriction (also referred to as intermittent calorie restriction 
(ICR)), or daily time-restricted feeding113,114. Periods of IF stimulate reduced insulin and 
increased glucagon, resulting in increased lipolysis and fatty acid oxidation to provide 
alternate substrates for energy production. These metabolic alterations are 
accompanied by reductions in several cancer-related risk factors including reduced 
serum glucose, insulin resistance, inflammation, and circulating IGF-1115. Preclinical 
studies with IF consistently exhibit a cancer preventative effect with reduced rates of 
tumor growth for multiple cancer types including lymphoma,116 breast, lung, ovarian, 
hepatic, and pancreatic115,117,118.  To our knowledge there is no published data on IF 
and cancer incidence in human subjects, although there are reports of favorable effects 
of IF in overweight humans, including improved adipokine ratios and reduced growth 
factor signaling and inflammatory markers118,119, suggesting the reported preclinical 
anticancer effects of IF may be translatable to humans.  
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One IF regimen being examined as primary prevention strategy for breast cancer 
is the 5:2 diet, which involves 5 days/week of a healthy diet, such as the Mediterranean 
diet, with two consecutive days of a low calorie, low carbohydrate diet.  The 
Mediterranean diet is primarily a plant-based diet high in fruits, vegetables, whole 
grains, legumes and nuts. Compared with North American dietary patterns, the 
Mediterranean diet has been associated with better control of body weight, reduction of 
cancer risk biomarkers and decreased cancer incidence120-124. The diet results in 
favorable modulation of inflammation, oxidative stress, and growth factor signaling. 
Clinical trials have shown that the 5:2 diet is as effective as, if not superior to, CCR in 
reducing weight and improving serum levels of metabolic and inflammatory mediators in 
overweight and obese individuals119. 
IF also improves antitumor immune functions in lean, tumor-bearing mice. 
Alternate day fasting for 2 weeks decreases tumor growth and reduces the number of 
tumor-infiltrating macrophages and frequency of M2-like macrophages125, which exert 
immunosuppressive functions126. A fasting-mimicking diet, which involves 4-day cycles 
of very low caloric intake every two weeks, enhances tumor CD8 T cell recruitment and 
decreases regulatory T cell abundance within the mammary tumor bed following 
treatment with the chemotherapeutic agent doxorubicin127. Moreover, prolonged cycles 
of fasting have also been shown to protect immune cells during chemotherapy128. 
Low-fat diet 
Numerous clinical studies have examined the effects of low-fat (LF) diet 
interventions on cancer risk.  Clinical trials with risk biomarker end points demonstrate 
that adherence to LF diet over a two-year period results in normalization of glucose 
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metabolism and reduction in growth factor signaling as well as favorable modulation of 
adipokine levels.129 In the Women’s Health Initiative clinical trial, nearly 50,000 
postmenopausal women were followed for an average of 8.1 years after random 
assignment to a LF diet with high fruit, vegetable, and grain intake or a comparison 
group. Analyses of this study indicate that a LF diet does not decrease overall risk of 
invasive cancer.130,131 When the data were analyzed by specific cancer type, no 
decrease in invasive breast,132 colorectal,133 endometrial,130 or melanoma134 cancer risk 
was observed, but the diet intervention did decrease ovarian cancer risk.130 Other 
randomized clinical trials have also demonstrated that LF diet intake does not reduce 
breast cancer risk135 or adenoma recurrence,136,137 though a 35% decrease in the odds 
ratio was observed for “super compliers” in the latter trial.138 
Researchers have also examined the impact of a LF diet on cancer outcomes in 
several clinical trials, including the Women’s Health Initiative trial, which found a 
reduction in breast cancer mortality in the diet intervention group,139 but no decrease in 
total cancer mortality.131 The Women’s Intervention Nutrition Study further demonstrated 
that LF diet significantly increases relapse-free survival in early-stage breast cancer 
patients, with greater effects seen in subjects with estrogen receptor negative tumors.140 
However, the Women’s Healthy Eating and Living trial, which also enrolled early stage 
breast cancer patients, found no reduction in breast cancer recurrence or mortality with 
LF diet,141 unless the analysis was limited to subjects without post-treatment hot 
flashes.142 Others have examined the effects of short-term LF dietary interventions on 
biomarkers in prostate cancer patients in so-called “window trials” conducted 
immediately prior to and after pre-radical prostatectomy. A LF, fish oil-supplemented 
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diet decreased prostate cancer cell proliferation, though fish oil may be the primary 
mediator of this effect.143 In support of this hypothesis, proliferation rates were also 
significantly reduced in men on a flaxseed-supplemented diet, but not in those that 
followed a LF diet without flaxseed.144 To our knowledge no studies have investigated 
the effects of LF diet on the tumor immune microenvironment. However, one small 
randomized control trial found that implementation of LF diet in hyperlipidemic 
individuals with an average BMI of 26.2 resulted in no significant changes in lymphocyte 
proliferation, interleukin-1, interleukin-2, or prostaglandin production145. 
Knowledge Gaps, Central Hypothesis, and Questions Tested 
 Given that advanced age and obesity are associated with similar degrees of 
inflammatory and immune dysregulation and also exert comparable increases in a 
woman’s risk of developing BC, the goal of my dissertation was to first determine in 
preclinical models if advanced age promotes mammary tumor growth. Once 
establishing that advanced age, like obesity, accelerates tumor growth I tested whether 
advanced age and obesity promote mammary tumor progression through overlapping 
mechanisms. After determining that advanced age and obesity converge on mammary 
and tumoral transcriptional changes indicative of an inflamed, immunosuppressive 
mammary adipose and immunosuppressed mammary tumor microenvironment, I tested 
whether various dietary interventions enhance antitumor immunity in aged, obese, and 
aged obese mice. My central hypothesis was that immune aberrations associated with 
advanced age and obesity promoted acquisition of an immune suppressed mammary 
tumor microenvironment and as a result enhanced mammary tumor progression 
(Figure 1.1). In addition, I posited that calorie restriction interventions, that exert 
immune modulatory effects in the context of advanced age and obesity, would 
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effectively reverse advanced age- and obesity-related tumor immunosuppression and 
as a result diminish tumor growth (Figure 1.1).  To address these hypotheses, 
experiments were conducted to answer the following questions: 
1. Does advanced age accelerate mammary tumor growth in mouse models of BC? 
2. Does advanced age promote inflammation within the tumor-adjacent mammary 
adipose that significantly overlaps that observed with obesity? 
3. Do advanced age and obesity foster overlapping transcriptional changes within 
the tumor microenvironment indicative of suppressed antitumor immunity?  
4. Does the combination of advanced age and obesity promote similar suppression 
of antitumor immune-related transcription? 
5. Will weight loss by either LF diet, CCR, or ICR enhance antitumor immune-
related transcription in mammary tumors from aged, obese, or aged obese mice, 




Tables and Figures 




Figure 1.1 Logic model for central hypotheses tested in this dissertation. 
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CHAPTER 2. ADVANCED AGE AND DIET-INDUCED OBESITY PROMOTE 
OVERLAPPING MAMMARY ADIPOSE INFLAMMATION AND TUMOR 
IMMUNOSUPPRESSION THAT CONTRIBUTES TO TUMOR GROWTH IN MOUSE 
MODELS OF BREAST CANCER 
Background 
Breast cancer (BC) is the most commonly diagnosed noncutaneous cancer 
among US women, and although current treatment paradigms provide relatively good 
survival, BC has the second highest mortality rate of all cancers in women1. Two major 
risk factors for BC are obesity and advanced age, which presents a critical public health 
concern due to global increases in obesity rates and population aging12,23. According to 
the World Health Organization, in 2016 approximately 13% of adults worldwide were 
obese, as defined by a body mass index of 30 kg/m2 or greater, which reflects a tripling 
of the obesity rate since 1975 12.The United States is disproportionately affected by 
obesity with an alarming 42.4% of adults classified as obese between 2017-201813. The 
world’s population is also growing older, and the proportion of individuals over the age 
of 65 globally is projected to increase from 9% in 2019 to 16% by 205023. Relative to 
other world regions, Europe and North America have higher proportion of individuals 
aged 65 and older (18% of their populations in 2019) that is expected to increase to one 
quarter of individuals within in those regions by 205023.  
 Obesity increases a woman’s risk of BC development, predominantly in 
postmenopausal women, and confers worse disease outcomes, including greater 
mortality and shorter time to disease recurrence, in both premenopausal and 
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postmenopausal patients with BC14,15. Obesity-related increases in BC incidence and 
progression are recapitulated in preclinical models of BC, which has allowed 
investigation into underlying mechanisms17,19. Obesity enhances BC progression, in 
part, through propagation of low-grade, chronic inflammation systemically and within the 
mammary adipose microenvironment68. Expansion of adipose tissue in response to 
overnutrition increases adipocyte dysfunction and death as well as release of cytokines, 
chemokines and cellular contents into the surrounding tissue68. Multiple inflammation-
related pathways are thus triggered, including: i) NOD-like receptor signals in response 
to release of damage-associated molecular proteins;  ii) Toll-like receptors in response 
to free fatty acids; and iii) NF-κB signaling in response to cytokines and chemokines that 
facilitate the recruitment and activation of proinflammatory immune cells68,71. 
Constitutive stimulation of the immune system in states of chronic, low-grade 
inflammation such as obesity promotes an adipose microenvironment abundant in 
proinflammatory mediators and the emergence of immunosuppressive cell types 
conducive for rapid tumor growth. Proinflammatory cytokines can directly stimulate 
tumor cell proliferation and indirectly modify vasculature and extracellular matrix within 
the mammary microenvironment to enhance tumor growth and metastatic potential68. 
Immune suppressor cells, including T regulatory cells, suppress key immune cells that 
participate in antitumor immunity including antigen-presenting dendritic cells and 
cytotoxic CD8 T cells41. Moreover, obesity increases expression of immune checkpoint 
pathways in effector T cells limiting antitumor immune responses78 and accelerates 




The impact of advanced age on the mammary tumor microenvironment and BC 
progression has been less studied than the obesity-BC link. Epidemiological data 
supports advanced age-related increases in BC incidence and mortality as 
approximately 45% of BC diagnoses and 60% of BC-related deaths occur in women 
aged 65 years or older25. Interestingly, both young age and old age at diagnosis is 
associated with reduced survival compared with middle-aged patients with BC27,29,146. In 
the case of young women (<40 years), reduced survival is attributed to increased 
development of aggressive tumor intrinsic features, including increased frequency of 
basal-like and triple negative subtypes as well as greater prevalence of driver mutations 
(i.e. BRCA1)146. Limited research has investigated advanced age-related BC 
progression; however, findings from two studies demonstrate that among patients with 
the same BC subtype (triple negative or hormone receptor negative), advanced age at 
diagnosis increased BC-specific mortality compared with younger patients27,29. Thus, 
when tumor intrinsic features are similar, tumor extrinsic features within the aged host 
contribute importantly to BC progression.  
In light of the increasing importance of both obesity and advanced age as BC risk 
factors, and the mechanistic parallels between obesity and aging (including similar 
propagation of systemic and adipose-specific low-grade, chronic inflammation and 
immune dysfunction), we posit that advanced age and obesity each promote mammary 
tumor growth through similar tumor-extrinsic mechanisms85. To test our hypothesis, we 
generated young (7 mos.) and aged (17 mos.) cohorts of normoweight and diet-induced 
obese female C57BL/6 mice and orthotopically transplanted mice with either claudin-low 
or basal-like mammary tumor cells.  We found that, relative to young control-fed mice, 
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both advanced age and obesity accelerated mammary tumor growth regardless of 
subtype and generated shared and distinct tumor gene expression profiles indicative of 
inflammation and immunosuppression in the tumor microenvironment. These findings 
demonstrate that convergent mechanisms drive BC growth in advanced aged and 
obese mice, relative to young lean mice. These age- and obesity-related biological 
differences will need to be considered when planning and interpreting preclinical studies 
in order to increase translation of preclinical findings to human BC.  
Methods 
Cell lines 
E0771 mammary carcinoma cells, purchased from ATCC (#CRL-3461),  and 
metM-Wntlung mammary carcinoma cells, developed in the Hursting laboratory, were 
labeled with lentiviral vector containing eGFP and NanoLuc (gifted by Dr. Antonio 
Amelio)147, and were maintained in RPMI1640 media (GIBCO Life Technologies) 
supplemented with 10% FBS, 10 mmol/L HEPES buffer, 2 mmol/L L-glutamine, and 1% 
penicillin/streptomycin. Cells utilized for tumor studies were found to be negative for 
mycoplasma (cat. #30-1012K, ATCC). 
Animal studies 
All animal protocols were approved by the University of North Carolina at Chapel 
Hill Institutional Animal Care and Use Committee (IACUC) and carried out in 
compliance with all guidelines and regulations. 
Advanced aged and diet-induced obese mice: To generate aged cohorts of 
normoweight control and obese mice, 6-8-week-old female C57BL/6J mice (stock 
#000664, The Jackson Laboratory, Bar Harbor, ME) were placed on either a low-fat, 
control diet (n=30, 10% kcal from fat; #D12450J, Research Diets Inc., New Brunswick, 
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NJ) or high-fat, DIO diet (n=30, 60% kcal from fat; #D12492), respectively. When aged 
cohorts were 12 months old, young cohorts of normoweight control and obese mice 
were generated by administering 6-8-week-old female C57BL/6J mice (#000664, The 
Jackson Laboratory) control (n=44) and DIO (n=20 mice) diets, respectively. Four 
months later, blood was collected from all mice via submandibular bleed, processed and 
serum stored for subsequent marker analyses. Prior to tumor injection, two young 
control and two aged DIO mice were found dead (causes unknown), two aged DIO mice 
developed a head tilt and were euthanized, and one aged DIO mouse developed 
dermatitis and was euthanized. One month later, half of young control, young DIO, and 
aged control groups were randomized to receive mammary fat pad (MFP; 4th mammary 
gland) injection with metM-Wntlung cells (1.5 x 104 cells/50 μL PBS); the other half of 
each group was injected with E0771 cells (2 x 104 cells/50 μL PBS). All aged DIO mice 
received MFP injection with E0771 cells. Mice were palpated biweekly until the majority 
of one of the experimental groups per cell line reached maximum allowable size, 
defined as a diameter of 1.5 cm measured in any direction. During the tumor growth 
period, some mice had to be removed from the metM-Wntlung arm of the study due to 
tumor ulceration (1 young control, 4 young DIO, and 6 aged control mice), terminal 
dermatitis (1 aged control mouse), poor health (1 aged control mouse), or death by 
unknown cause (1 young control mouse). In the E0771 arm of the study, mice were 
removed from the study due to tumor ulceration (1 young control and 1 aged DIO mice), 
terminal dermatitis (1 young control, 1 young DIO, and 3 aged DIO mice), reaching 
maximum tumor size (1 aged DIO mouse), poor health (1 aged DIO mice), or death by 
unknown cause (1 aged DIO mouse). Mice still alive 1 month following tumor inoculation 
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were euthanized, tumors weighed, and tissues collected (including, tumors, MFP, and 
lung). Due to low tumor engraftment in young control mice that received E0771 cells, 
these mice continued on study for an additional two weeks beyond the time the other 
groups were terminated. 
CD8 Depletion Experiment: Female C57BL/6 mice (2 months old, n=54; 
#000664, The Jackson Laboratory, Bar Harbor, ME) were acquired, placed on the low-
fat control diet, and allowed to acclimate for one week. Mice received either 
intraperitoneal injection with PBS (n=6), 200 μg anti-mouse CD8α depleting antibody 
(n=24; clone 2.43, BioXCell), or rat IgG2B isotype (n=24; LTF-2, BioXCell) 2 days prior 
to tumor cell injection, the day of tumor cell injection, and every 4 days following for up 
to 8 treatments.  Mice were injected with 1.5 x 104 metM-Wntlung cells into the 4th 
mammary fat pad. Tumor growth was monitored twice weekly using electronic calipers. 
To determine efficacy of the CD8α antibody and duration of CD8+ T-cell depletion, 6 
randomly chosen mice per group were euthanized at 13, 17, 21, and 25 days following 
tumor inoculation and tumors and spleens collected. At 2 timepoints, 17 and 25 days 
following tumor inoculation, tumors from the 6 randomly chosen mice per group were 
dissociated into a single cell suspension using Miltenyi Biotec’s Tumor Dissociation kit 
(#130-096-730) and gentleMACs Dissociator, according to manufacturer’s protocol, and 
splenocytes were isolated as described previously148. Single cell suspensions were 
treated with TruStain FcX to bind Fc receptors and block non-specific binding to 
immunoglobulins (#101320, BioLegend) and then stained with Zombie UV fixable 
viability dye (#423108, BioLegend) and antibodies against CD45 (#103106, BioLegend), 
CD3 (#100306, BioLegend), and CD8 (#100712, BioLegend). Fluorescence intensity 
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was measured using Becton Dickinson LSRII through the UNC the Flow Cytometry 
Core Facility. 
Body composition measures  
Body composition was assessed via quantitative magnetic resonance imaging 
(Echo Medical Systems, Houston, TX) prior to tumor inoculation and at endpoint. 
Imaging resulted in measurements of lean mass, fat mass and total water mass. 
Percent body fat mass and lean mass was calculated by dividing fat mass or lean mass, 
respectively, by total body weight. 
Tumor immunohistochemistry (IHC) 
Formalin-fixed and paraffin-embedded (FFPE) tumors (8 randomly selected 
mice/group) were sectioned and mounted on slides. Two tumor sections 100 μm apart 
were stained via immunohistochemistry (IHC) for antibodies against Ki67 (#VP-RM04, 
Vector Laboratories), CC3 (#9661, Cell Signaling), CD3 (#ab16669, Abcam), and CD8 
(#98941, Cell Signaling). Staining was analyzed using QuPath software149. 
Metastasis analysis  
FFPE lungs (8 randomly selected mice/group) were sectioned and stained with 
hematoxylin and eosin or anti-green fluorescent protein (GFP; #GFP-1020, Aves Labs, 
Tigard, OR) dilution. Presence of GFP+ lung metastases were quantified using Aperio 
ImageScope (Leica Biosystems, Wetzlar, Germany). Trained pathologist Stephanie 
Montgomery, DVM, confirmed that GFP+ lesions were metastases. 
RNA profiling and gene set enrichment analysis (GSEA) 
Total RNA was extracted from flash-frozen adjacent mammary and tumor 
samples using TRIzol Reagent (Sigma-Aldrich) and RNeasy Mini Kit (Qiagen) according 
to manufacturer's instructions. Adjacent mammary and matched tumor samples were 
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selected from mice with tumor masses closest to the median of their experimental group 
(n=6/group).  RNA quality was assessed using an Agilent 2100 Bioanalyzer. Gene 
expression profiling was performed by the Functional Genomics Core at the University 
of North Carolina. In brief, GeneChip™ WT PLUS Reagent Kit (Applied Biosystems, 
#902414) was used to synthesize fragmented and labeled sense-strand cDNA from 
total RNA, according to the manufacturer’s protocol. Fragmented and labeled cDNA 
was used to prepare a hybridization cocktail with the Affymetrix GeneTitan Hybridization 
Wash and Stain Kit for WT Arrays (#901622). Hybridization, washing, staining and 
scanning of the Affymetrix Clariom™ S Assay HT (#902972) was carried out using the 
Affymetrix GeneTitan Instrument (Applied Biosystems). Transcriptome Analysis Console 
Software v 4.0 was used for basic data analysis and quality control.   
Bulk gene expression data was analyzed using gene set enrichment analysis 
(GSEA) in combination with Hallmark and C7 Immunologic gene sets150-152. Two 
phenotypic comparisons were performed aged control vs young control and young DIO 
vs young control. Significantly enriched gene sets were defined as false discovery rate 
(FDR) q-value < 0.05. Gene sets commonly enriched or underrepresented across 
comparisons were identified and hypergeometric analysis performed to test significance 
of the overlap. Leading edge analysis (LEA) was performed on gene sets commonly 
enriched or underrepresented across comparisons150,151. The probability of overlapping 
gene set enrichment and leading edges was computed via hypergeometric analysis. 
Spearman correlation analyzed differential contribution of each leading edge gene to 




Collected animal study data are presented as mean ± SD. Statistical analyses 
were performed using GraphPad Prism software (GraphPad Software Inc.) and 
statistically significant differences defined by p <0.05. Differences across two groups 
were analyzed by t-test. Differences across three or more experimental groups were 
analyzed using one-way ANOVA, followed by Tukey post hoc test, if comparing means 
to young control, or Dunnett post hoc, if comparing each means to every other mean. 
Results 
Advanced age and DIO increase primary tumor growth in a mouse model of 
claudin-low BC  
To test whether advanced age and DIO exert similar enhancing effects on 
claudin-low mammary tumor growth, three experimental groups were evaluated: 1) 
young mice fed a low-fat, control diet (young control), 2) aged mice fed a low-fat control 
diet (aged control), and 3) young mice fed a high-fat, DIO diet (young DIO) (Figure 
2.1A). As expected, the DIO diet increased body weight in young DIO compared with 
young control mice (Figure 2.1B). Aged control mice, relative to young control mice, did 
not significantly differ in body weight (Figure 2.1B). However, young DIO and aged 
control mice, relative to young control mice, all displayed increased percentage of body 
fat relative to total body weight and decreased percentage of lean mass relative to total 
body weight (Figures 2.1C-D). Mammary tumor growth and progression were 
monitored biweekly following transplantation of metM-Wntlung cells, a murine model of 
metastatic claudin-low BC19, into the fourth mammary fat pad of mice (Figure 2.1E). 
The aged control mice and young DIO mice displayed increased primary tumor growth 
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compared with young control mice; the group with the greatest ex vivo tumor mass was 
the young DIO mice (Figure 2.1F).  
Aged control and young DIO mice, relative to young control mice, have 
differential enrichment for inflammatory- and immune-related transcripts within 
the tumor-adjacent mammary fat pad (TA-MFP) 
Obesity induces profound effects on mammary adipose tissue that facilitates 
accelerated tumor progression, including increased  expression of proinflammatory 
cytokines and shifting of immune cells toward immunosuppressed phenotypes68. 
Parallels have been drawn between the effects of obesity and advanced age on visceral 
adipose depots, as advanced age similarly increases abundance of proinflammatory 
factors and alters the visceral adipose immune landscape85. However, the effects of 
advanced age on mammary adipose and the effects of age-related adipose 
inflammation on breast cancer progression remains largely unexplored.  
To identify major cellular pathways and processes altered in the aged and obese 
tumor-adjacent mammary fat pad (TA-MFP), we performed GSEA with Hallmark gene 
sets. Aged controls were enriched for 14 gene sets and young DIO for 8 gene sets 
compared with young controls (Table 2.1). Hypergeometric analysis of commonly 
enriched gene sets indicated a statistically significant degree of overlap (p=3.52 x 10-3).  
Commonly enriched gene sets were related to immune signaling (e.g. TNFA Signaling 
via NFKB, IL6/JAK/STAT3 Signaling, and IFNG Response) and Epithelial Mesenchymal 
Transition, a process implicated in metastatic progression (Figure 2.A)153.  
To determine which genes positively contributed to the enrichment of immune-
related gene sets in aged control and young DIO mice, leading edge analysis (LEA) was 
performed. We observed significant overlap between the two leading edges, indicating 
that advanced age and DIO induce common immune-related transcriptional alterations 
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within the TA-MFP (Figure 2.2B). Spearman correlation analysis of gene-level 
contributions to DIO-related leading edges versus age-related leading edges revealed a 
significant and strong correlation (Figure 2.2C). 
Given the preponderance of immune-related gene sets enriched in both aged 
control and young DIO TA-MFP, we sought to determine whether this relationship was 
robust to further analysis using immunologic gene sets (C7 immunologic gene sets)152. 
C7 immunologic gene sets are derived from diverse cell states and perturbations of the 
mouse and human immune system152. Aged control TA-MFP were enriched for 1188 
gene sets and young DIO TA-MFP for 310 gene sets relative to young control. 
Hypergeometric testing revealed significant overlap in C7 gene sets enriched in aged 
control and young DIO (Figure 2.2D). LEA identified statistically significant degree of 
overlap in age- and DIO-related leading edge genes (Figure 2.2E, Table 2.2). 
Spearman correlation analysis revealed significantly concordant gene-level 
contributions to age- and DIO-related leading edges (Figure 2.2F).  
The overlapping leading edge genes from gene sets enriched in aged control and 
young DIO versus young control (Figure 2.2G) included: 1) multiple chemokine, 
cytokine, and interleukin genes whose products would promote immune cell recruitment 
and stimulation within the mammary adipose; 2) genes related to macrophages and 
monocytes; and 3) numerous Toll-like and NOD-like receptor genes that can be 
activated by free fatty acids and damage-associated molecular proteins71.  
We also noted underrepresentation of gene sets in TA-MFPs from aged control 
and young DIO mice compared with young control mice. TA-MFPs from aged control 
and young DIO mice were underrepresented for 6 and 11 Hallmark gene sets 
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respectively relative to TA-MFPs from young control mice (Table 2.1). Hypergeometric 
analysis determined significant overlap in underrepresented gene sets (p=2.91 x 10-5). 
Commonly underrepresented gene sets were related to adipogenesis and metabolism 
(e.g. Oxidative Phosphorylation and Fatty Acid Metabolism) suggesting differential 
regulation of these processes with advanced age and obesity (Figure 2.3A). LEA 
revealed significant overlap in DIO- and age-related leading edges (Figure 2.3B). 
Spearman correlation analysis of gene-level contributions to DIO-related leading edges 
versus age-related leading edges revealed a significant and strong correlation (Figure 
2.3C).  
Advanced age and DIO induce transcriptional changes within the tumor related to 
cellular proliferation, epithelial mesenchymal transition, and angiogenesis 
Tumors from aged control and young DIO mice, relative to young control mice, 
displayed enrichment for 11 and 12 Hallmark gene sets, respectively (Table 2.3). 
Hypergeometric analysis determined significant overlap of enriched gene sets 
(p=1.12x10-4). Commonly enriched gene sets reflect multiple processes that have been 
linked to tumor growth and progression including cellular proliferation (e.g., mitotic 
spindle and E2F targets), epithelial mesenchymal transition, and angiogenesis, among 
others (Figure 2.4A). LEA showed significant overlap in DIO- and age-related leading 
edge genes (Figure 2.4B). Spearman correlation analysis of gene-level contributions to 
DIO-related leading edges versus age-related leading edges revealed a significant and 
strong correlation (Figure 2.4C).  
Advanced age and DIO induce immunosuppression and reduce CD8+ T cell 
abundance within the mammary tumor microenvironment  
Contrasting the TA-MFP, mammary tumors from aged control and young DIO 
mice were underrepresented for immune-related gene sets, relative to mammary tumors 
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from young control mice. GSEA with Hallmark gene sets revealed underrepresentation 
of 5 gene sets in aged control and 8 in young DIO relative to young control tumors 
(Table 2.3). Hypergeometric analysis demonstrated significant overlap of 
underrepresented gene sets (p=1.39x10-3). The majority of overlapping 
underrepresented gene sets were related to immune signaling (i.e. inflammatory 
response, allograft rejection, and IFNG Response; Figure 2.5A). LEA of immune-
related gene sets revealed significant overlap in leading edge genes (Figure 2.5B, 
Table 2.4). Spearman correlation analysis of gene-level contributions to DIO-related 
leading edges versus age-related leading edges revealed a significant and strong 
correlation (Figure 2.5C).  
To investigate differences in immune-related signaling, we conducted GSEA with 
C7 immunologic gene sets. Aged control tumors were underrepresented for 44 gene 
sets and young DIO for 703 gene sets relative to young control. 41 gene sets were 
underrepresented in both aged control and young DIO demonstrating significant overlap 
(Figure 2.5D). LEA showed significant overlap in leading edge genes (Figure 2.5E). 
Spearman correlation analysis of gene-level contributions to DIO-related leading edges 
versus age-related leading edges revealed a significant and strong correlation (Figure 
2.5F).  
Many of the leading edge genes underrepresented in aged and DIO tumors were 
related to T cell receptor signaling (e.g. Cd3d, Cd8a, and Zap70), immune activation 
(e.g. Ifng, Cxcl11), and cytotoxicity (e.g. Prf1 and Gzma; Figure 2.5G, Table 2.4). We 
were particularly intrigued by underrepresentation of genes encoding CD3 and CD8 
receptors as they are markers of cytotoxic CD8 T cells. Therefore, we used IHC 
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analysis to test whether differential gene expression translated to differences in 
abundance of cells expressing CD3 and CD8 within mammary tumors. Mammary 
tumors from aged control and young DIO mice, relative to young control mice, showed 
significantly lower percentages of cells expressing CD3 and CD8 (Figures 2.5H-I).  
Reduction of CD8+ T cell immune surveillance enhances growth of metM-Wntlung 
tumor cells in vivo 
These findings suggest that obesity and advanced age enhance mammary tumor 
growth through reduced CD8 T cell-mediated immune surveillance within the mammary 
tumor microenvironment. To test if CD8 T cell surveillance constrains growth in our 
claudin-low model, female C57BL/6J mice were treated with either anti-mouse CD8α-
depleting antibody, rat IgG2B isotype control, or a vehicle control beginning two days 
prior to mammary injection with metM-Wntlung cells (Figure 2.6A). Flow cytometric 
analysis at an interim timepoint (17 days after tumor inoculation) and study endpoint (25 
days after tumor inoculation) confirmed depletion of CD3+CD8+ T cells in the spleens 
and tumors of αCD8-treated mice compared with IgG2B isotype control (Figures 2.6B-
E). As anticipated, there was negligible CD8 detected within the total CD45+ immune 
cell populations isolated from spleens and tumors of αCD8-treated mice (Figures 2.6F-
G). We noted no difference in tumor growth between PBS- and IgG-treated mice 
(Figure 2.6H). Depletion of CD8 T cells augmented metM-Wntlung cell growth, resulting 
in greater ex vivo tumor mass among αCD8-treated mice at all measured timepoints 
(13, 17, 21 and 25 days following tumor injection) compared with isotype controls 
(Figures 2.6H-K).  
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The combination of advanced age and obesity exacerbates mammary tumor 
growth in a mouse model of basal-like BC 
Having demonstrated that advanced age and obesity separately promote 
mammary tumor growth, we next wanted to test if the combination of advanced age and 
obesity further enhances tumor progression. We generated cohorts of young control, 
young DIO, aged control, and aged DIO mice (Figure 2.7A). Advanced age alone did 
not alter body weight, percentage of body fat mass, or percentage of lean mass in aged 
control mice compared with young control (Figure 2.7B-D). In contrast, DIO feeding 
resulted in significantly greater body weight and percentage body fat mass relative to 
aged-matched control fed mice (Figure 2.7B-C). Further, the combination of advanced 
age and DIO feeding resulted in the greatest body weight, and percentage body fat 
mass, relative to all other groups (Figure 2.7B-C). Changes in adiposity with DIO 
feeding resulted in reduced percentage lean mass (Figure 2.7D). 
To determine the effects of advanced age, obesity, and the combination of 
advanced age and obesity on tumor progression, mice received mammary injection with 
E0771 cells, a model of metastatic basal-like BC (Figure 2.7E). Advanced age and 
obesity increased tumor burden, as aged control, young DIO, and aged DIO mice all 
exhibited increased tumor engraftment relative to young control mice (Figures 2.7F). 
Only one young control mouse developed a palpable tumor. This mouse also developed 
dermatitis and had to be euthanized prior to tumor endpoint. Due to their minimal tumor 
progression, young control mice were excluded from subsequent analyses. Aged DIO 
mice had greater ex vivo tumor mass and metastatic burden compared with aged 
control mice (Figures 2.7G-H). Differences in tumor mass and metastases between 
aged DIO and young DIO did not reach statistical significance (Figure 2.7G-H).  
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Aged DIO mice exhibit heightened inflammatory perturbations and tumor immune 
suppression compared with aged control mice 
Given that the combination of advanced age and DIO in mice increases adiposity 
and tumor burden to a greater extent than either advanced age or DIO alone, we 
assessed whether aged DIO mice exhibit worsened systemic inflammation and/or 
increased levels of tumor-promoting serum cytokines, relative to all other groups. 
Analyte levels of 32 cytokines were measured in serum collected prior to tumor 
injection. Differential analyte levels were detected in 6 of the cytokines measured 
(Figure 2.8A-E), including elevation of three chemokines in serum from the aged DIO 
mice, relative to the other groups, that orchestrate tumor supportive actions: CXCL13, 
CCL7, and CCL11(Figure 2.8A-C)154-156.  
We also postulated that aged DIO mice would exhibit greater 
immunosuppression in the tumor microenvironment compared with aged control mice. 
Tumor transcriptional data was collected, and pairwise pathway enrichment between 
aged DIO and aged control tumors was determined using GSEA and Hallmark gene 
sets. Immune-related Hallmark gene sets were underrepresented in aged DIO tumors, 
relative to aged control tumors (Figure 2.8F; Table 2.5). Underrepresented gene sets 
included allograft rejection, IFNG response, and inflammatory response gene sets 
(Figure 2.8F; Table 2.5), which were also underrepresented in tumors from aged 
control and young DIO mice compared with young control mice in our study of claudin-
low BC (Figure 2.5A).  GSEA with C7 immunologic gene sets identified 177 gene sets 
underrepresented in aged DIO compared with aged control. Underrepresented gene 
sets included those related to dendritic cell stimulation, increased memory vs exhausted 
CD8 T cell phenotypes, and CD4 T cell stimulation. Fewer gene sets were enriched in 
 
39 
aged DIO compared with aged control (121 gene sets). Enriched gene sets included 
those related to reduced dendritic cell stimulation, regulatory T cell signaling, and 
TGFβ1 signaling in T cells that suppress immune surveillance and promote tumor 
immune evasion157. Leading edge analysis identified suppression of T cell markers (e.g. 
Cd3e, Cd8a, Cd4), related signaling molecules (e.g. Lck), as well as cytotoxic mediators 
(e.g. Prf1, Gzma, Gzmb) in aged DIO tumors (Figures 2.8G; Table 2.6).  
Discussion 
 The aging of the population in the United States and worldwide coupled with the 
global obesity epidemic is cause for public health concern. Advanced age and obesity 
increase an individual’s risk of developing and dying from numerous chronic diseases, 
including BC. This highlights the necessity to study and uncover the mechanisms 
through which advanced age and obesity promote disease progression. Our work 
focuses on the impact of advanced age and obesity on BC, the most commonly 
diagnosed and second deadliest cancer among women in the US. Research conducted 
by our lab as well as others has investigated obesity-associated BC progression and 
demonstrated that mammary adipose inflammation and tumor immunosuppression are 
major contributors. In contrast, mechanistic contributions of advanced age to BC 
progression remain largely unexplored. Our current study addresses this gap in the 
literature and tests whether advanced age and obesity promote BC growth through 
common biological underpinnings, a hypothesis stemming from parallels between the 
aged and obese host (e.g. chronic inflammation and immune dysfunction). Herein, we 
report that advanced age and obesity promote BC growth, and we identify common 
tumor-supportive biology induced with both advancing age and obesity. Specifically, we 
observed in aged control and young obese mice: 1) overlapping inflammatory- and 
 
40 
immune-related signatures within the TA-MFP; 2) similar suppression of immune-related 
transcripts within the mammary tumor microenvironment; and 3) reductions in tumoral 
cytotoxic CD8 T cells and related signaling. In addition, we demonstrate that obesity in 
the context of advanced age further exacerbates tumor burden and 
immunosuppression. 
Our findings are the first to demonstrate that advanced age accelerates 
progression of basal-like and claudin-low BC in preclinical models. At study endpoint, 
aged control and young DIO mice exhibited increased intramammary engraftment of 
basal-like E0771 cells and enhanced growth of claudin-low cells when compared with 
young control mice. This confirms previous reports from our lab as well as others 
demonstrating tumor-promoting effects of DIO in mouse models of BC17,19,83. On the 
other hand, there have been relatively few studies to date investigating the effects of 
age on mammary tumor growth. Sceneay J, et al. tested whether multiple mammary 
carcinoma cells exhibited differential growth kinetics in older (12 months old) versus 
younger (8-10 weeks old) mice32. At early timepoints, 4T1 tumors were significantly 
larger in older mice; however, at endpoint there was no significant difference in tumor 
size in the aged compared with younger mice32. On the other hand, Met1 tumors grew 
more slowly in older mice producing significantly smaller tumors compared with younger 
mice at 30 days post tumor inoculation32. Investigation in three different cell lines 
confirmed strain-specific differences with two cell lines (4T07 and 67NR)  having similar 
growth and one (McNeuA) having slower growth in older compared with younger mice32.  
Another report that 4T1 mammary carcinoma cells grew more slowly in 12-15-month-old 
mice compared with 2-3-month-old-mice33.  
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The inconsistency between these findings suggest that the effects of age on BC 
may be different across tumor cell lines and BC subtypes. There could also be 
biological differences in 17-month-old compared with 12-month-old mice that produce 
significant protumorigenic effects. The average lifespan of a laboratory mouse ranges 
from 23-32 months35. A 17-month-old mouse is approaching their average lifespan 
whereas a 12-month-old mouse is only half-way to their average lifespan. Marker of 
chronological age, such as cellular senescence, increase linearly with advancing age 
and increased abundance of senescent cells are observed in 18-month-old vs 12-
month-old mice37,158. Senescent cells, which often express a senescence-associated 
secretory phenotype (SASP) composed of inflammatory factors such as IL-6, IL-8 IL-1b, 
GM-CSF, and IFN-g, increase with age and are a major contributor to age-related 
inflammation (known as inflammaging)159. Cellular senescence mechanistically 
contributes to progression of multiple cancer types, including BC87. Specifically, in the 
context of BC, senescent cells and SASP expression promotes growth of preneoplastic 
and neoplastic cells, increases metastasis, and decreases chemotherapeutic 
response87,160. Given that BC is more prevalent in women of advanced age and the 
differential impact of advanced age-related biology on tumor growth in our models of 
claudin-low and basal-like BC, it will be important for future preclinical studies to 
consider age in their study design and data interpretation. 
In our study, acceleration of tumor growth with advanced age and obesity can be 
explained, in part, by convergent inflammatory- and immune-related transcriptional 
patterns in the TA-MFP. Notably, advanced age and obesity resulted in enrichment of 
IL-6/JAK/STAT3 signaling, which cultivates an immunosuppressive environment 
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through various mechanisms such as stimulating expansion of myeloid derived 
suppressor cells and controlling antitumor T cell responses161,162. Elevation of IL-6 has 
previously been observed in adipose tissue of aged and obese humans and animals, 
and is associated with poor prognosis in BC patients85,163-165. Inhibition of IL-6 improves 
tumoral Th1 responses, increases abundance of antigen specific CD8+ T cells within 
tumors, and diminishes tumor growth in a mouse model of melanoma166. Thus, 
advanced age and obesity promote immunosuppressive signaling within the mammary 
adipose directly adjacent to mammary tumor cells, which could result in paracrine 
exchange of immunosuppressive molecules and suppression of cells that participate in 
the antitumor immune response.   
We found that inflammatory and immunosuppressive signaling within the TA-
MFP was associated with tumor immunosuppression in aged control and young DIO 
mice. Specifically, aged control and young DIO tumors, relative to young control tumors, 
were underrepresented for inflammation- and immune-related gene sets including IFNG 
response. Consistent with these findings, Sceneay J, et al. found that tumors from mice 
12 months old and humans 65 years or older were underrepresented for IFNG response 
gene set compared with younger mice (8-10 weeks old) and humans (≤ 40 years old), 
respectively32.  IFN-g is a critical antitumor immunity mediator that is secreted by a 
variety of cell types, including CD8 T cells, and results in the upregulation of antigen 
presentation machinery and promotion of cytotoxic CD8 T cell differentiation and 
cytotoxic effector function73. In our study, leading edge analysis of commonly 
underrepresented immune-related gene sets in aged control and young DIO tumors, 
compared with young control, revealed that suppressed transcripts were related to 
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cytotoxic CD8 T cell signaling and cytotoxic effector functions. IHC analysis 
demonstrated reduced abundance of CD8 cells within the tumor microenvironment. 
Taken together, these findings indicate that advanced age and obesity reduce CD8 T 
cell abundance within mammary tumors and suppress transcripts relating to antitumor 
immunity.  
In patients with BC, decreased abundance of tumor-infiltrating CD8 T cells are 
associated with diminished overall survival and relapse free survival167. Preclinical 
studies have mechanistically proven that CD8 T cells control the tumor growth across 
many cancer models, including the basal-like E0771 BC model utilized in this study168. 
We tested if CD8 T cells impacted growth in our claudin-low BC model and found a 
similar CD8 T cell-mediated constraint of tumor growth. Thus, it is conceivable that 
reduced CD8 T cell surveillance within the tumors of aged control and young DIO mice, 
relative to young control mice, significantly contributes to observed acceleration in 
mammary tumor growth.  
Other studies have found that advanced age and obesity alters the function of 
tumor-infiltrating CD8 T cells. Sceneay J, et al. found that mammary tumors from aged 
mice had reduced frequency of tumor-infiltrating CD8+ T cells expressing IFN-g 
compared with younger mice32. Although these age-related CD8 T cell alterations did 
not result in accelerated tumor growth, they were associated with diminished response 
to immune checkpoint blockade therapies that target PD-L1 and CTLA432. Murine 
models of DIO demonstrate CD8 T cell dysfunction within melanoma and mammary 
tumors, characterized by tumoral CD8 T cells that exhibit increased expression of 
exhaustion markers (e.g. PD-1, Tim3, and Lag3), reduced proliferation, and decreased 
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transcription of effector molecules (e.g. Ifng and Gzmb)78,83. In these studies, DIO-
related alterations to CD8 T cell function were associated with increased tumor growth 
as well as enhanced response to an anti-PD-1 immunotherapy78. These data 
demonstrate that advanced age- and obesity-related effects on the tumor immune 
microenvironment result in differential therapeutic response.  
 This is the first preclinical study to our knowledge to test the combined effects of 
advanced age and obesity on mammary tumor growth. Prior to tumor inoculation, aged 
DIO mice, compared with aged control mice, young obese mice, and young control 
mice, had elevated serum levels of chemokines that orchestrate tumor supportive 
actions: CXCL13, CCL7, and CCL11. CXCL13 activates signaling pathways that 
promote proliferation, survival, migration, and metastatic BC154. CCL7 promotes BC cell 
proliferation and metastatic growth in preclinical models155. CCL11 potently stimulates 
growth and invasiveness of ovarian cancer cells, and serum levels are negatively 
correlated with relapse-free survival in ovarian cancer patients156. Enhanced serum 
expression of tumor supportive chemokines correlated with increased tumor burden in 
aged DIO mice compared with young control and aged control mice. We did not 
observe significant differences tumor burden between young DIO and aged DIO; 
however, our study may have been underpowered due to the large number of aged DIO 
mice removed from the study prior to endpoint. Further, we were unable to confirm 
advanced age- and obesity-associated tumor immunosuppression in this arm of the 
study due to low tumor engraftment in young control mice due to their relative 
resistance to mammary tumor development versus the other groups. Nevertheless, we 
were able to test the impact of DIO, in the context of advanced age, on the tumor 
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microenvironment. Aged DIO tumors were underrepresented for immune-related 
transcripts including those relating to CD8 T cell receptor, T cell receptor signaling, as 
well as cytotoxic effector molecules. Thus, we conclude that DIO in advanced age 
results in greater tumor burden that can be explained, in part, by suppression of 
transcriptional signatures indicative of antitumor immunity. 
There are several strengths to highlight regarding this research project. We were 
able to test our hypothesis in two independent preclinical models of BC that 
demonstrated consistent promotion of tumor growth with advanced age and obesity. 
The utilized murine mammary carcinoma cell lines model two distinct BC subtypes that 
are associated with poorer prognoses and currently lack targeted therapies5,9-11. To 
determine mechanistic explanations for accelerated tumor growth in aged and obese 
mice, we performed rigorous transcriptional analyses to test whether advanced age and 
obesity convergently promoted mammary adipose inflammation and tumor 
immunosuppression, features implicated in obesity-associated BC progression. Finally, 
we performed a mechanistic study to test if differential abundance of tumoral CD8+ T 
cells could explain differential tumor growth in aged and obese mice.  
Limitations of this study include the use of murine models to study human BC as 
biological differences exists between the two species. However, literature supports 
conservation of certain aspects of age- and obesity-associated immune dysfunction 
across species78,152. Nevertheless, more translational research efforts are needed to 
determine whether these preclinical findings are consistent with human aging and 
obesity. In addition, due to low engraftment in young control mice in the basal-like tumor 
model, we were unable to effectively study the interactive effects of advanced age and 
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obesity on BC. We also had to censor several aged DIO mice due to various adverse 
health effects. Given the significant impact of advanced age and obesity on BC 
separately, it will be important for future studies to determine whether advanced age 
and obesity interactively impact BC progression. 
In conclusion, these findings reveal striking similarities in advanced age- and 
obesity-related biology that contributes to accelerated mammary tumor progression. 
The differential effects of advanced age and obesity on the mammary tumor 
microenvironment may necessitate alternative therapeutic approaches for patients with 
advanced age, obesity, or the combination of advanced age and obesity. Further 
research is needed to fully elucidate mechanisms underlying advanced age- and 
obesity-related BC progression and aid in the development of interventions to improve 
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Figure 2.1 Advanced age and diet-induced obesity (DIO) increase mammary 
tumor growth.  A) Study Schematic. B) Body weight, C) % body fat mass and D) % 
lean mass measured prior to tumor engraftment. E) In vivo tumor growth monitored by 
caliper measurement of tumor length (L), the greatest diameter, and width (W), the 
diameter perpendicular to the L, and the equation V=L x W2 x 0.5. F) Ex vivo primary 
tumor mass. Data presented as mean ± SD. Differences across all groups analyzed 
using one-way ANOVA and Tukey post hoc test. Asterisks indicate differences in 





Figure 2.2 Advanced age and obesity induce convergent inflammatory alterations 
within the tumor-adjacent mammary adipose. Hallmark gene sets commonly 
enriched in tumor adjacent mammary fat pad (TA-MFP) of aged control vs young control 
and young DIO vs young control mice determined following gene set enrichment 
analysis (GSEA). B) Leading edge analysis (LEA) of commonly enriched immune-
related Hallmark gene sets. C) Frequency of the genes occurring in the leading edge of 
enriched gene sets verses gene rank. D) C7 Immunologic gene sets commonly 
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enriched in TA-MFP of aged control vs young control and young DIO vs young control 
mice were determined following GSEA. E) LEA of all commonly enriched C7 gene sets. 
F) Frequency of the genes occurring in the leading edge of enriched gene sets verses 
gene rank. G) Heat map of select leading edge genes. Significant gene set enrichment 
defined as FDR q-val <0.05. Significance in overlap of leading edge genes analyzed 
using hypergeometric test. Correlation between the gene rank of leading edge 




Table 2.1 Hallmark gene set enrichment in tumor-adjacent mammary fat pads (TA-
MFP) from aged control mice and young DIO mice, relative to young control.  
 
 
TA-MFP, tumor-adjacent mammary fat pad; DIO, diet-induced obese; NES, normalized 
enrichment score; FDR, false discovery rate 
  
NES FDR q-val NES FDR q-val
HALLMARK_IL6_JAK_STAT3_SIGNALING 2.38 < 0.001 1.94 < 0.001
HALLMARK_INFLAMMATORY_RESPONSE 2.22 < 0.001 1.95 < 0.001
HALLMARK_INTERFERON_GAMMA_RESPONSE 2.50 < 0.001 1.94 < 0.001
HALLMARK_COMPLEMENT 1.91 < 0.001 1.71 0.003
HALLMARK_TNFA_SIGNALING_VIA_NFKB 1.83 0.001 1.75 0.002
HALLMARK_COAGULATION 1.87 0.001
HALLMARK_ALLOGRAFT_REJECTION 2.59 < 0.001
HALLMARK_INTERFERON_ALPHA_RESPONSE 2.05 < 0.001
HALLMARK_IL2_STAT5_SIGNALING 1.38 0.044
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 1.70 0.003 2.09 < 0.001
HALLMARK_MYOGENESIS 2.51 < 0.001
HALLMARK_ADIPOGENESIS -2.49 < 0.001 -2.24 < 0.001
HALLMARK_SPERMATOGENESIS -1.39 0.044
HALLMARK_FATTY_ACID_METABOLISM -2.13 < 0.001 -2.01 < 0.001
HALLMARK_OXIDATIVE_PHOSPHORYLATION -2.36 < 0.001 -1.91 < 0.001
HALLMARK_CHOLESTEROL_HOMEOSTASIS -1.69 0.003 -1.79 < 0.001
HALLMARK_BILE_ACID_METABOLISM -1.66 0.004 -1.64 0.004
HALLMARK_XENOBIOTIC_METABOLISM -1.30 0.082
HALLMARK_E2F_TARGETS 2.18 < 0.001
HALLMARK_G2M_CHECKPOINT 2.11 < 0.001
HALLMARK_MITOTIC_SPINDLE 1.87 < 0.001
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Table 2.2 Leading edges of immune-related gene sets enriched in tumor-adjacent 
mammary adipose of aged control and young DIO mice vs young control. 
 
Actn2 Csf3r Il1r1 Pcsk9 Stat2 Aqp9 Rasgrp1 Acvrl1 Nr4a3
Acvr1b Ctsh Il1r2 Pde4b Stat3 Bcl2a1 Relb Adra2b P2ry2
Adam9 Ctss Il2rg Pdgfc Stat4 Birc2 Rgs1 Atf3 Pdgfb
Adar Cxcl13 Il3ra Pdpn Tacr1 Casp7 Rtp4 Best1 Pdlim5
Adm Cybb Il4r Pik3cg Tdrd7 Ccl22 Samd9l Bmp2 Pdp1
Adora2b Cyr61 Il6 Pik3r5 Tfpi2 Ccl5 Scg3 Bpgm Plau
Aplnr Ddx58 Il7 Pim1 Tgfb1 Ccr7 Serpinc1 Btg2 Plscr1
Apoa4 Ddx60 Il7r Pla2g7 Timp1 Cd40lg Slamf7 Ca2 Pmepa1
Auts2 Dhx58 Inhbe Plaur Tlr1 Cd55 Slc1a2 Calcrl Pnp
B4galt5 Dock10 Irf5 Plek Tlr2 Cd69 Snn Casp8 Ppp1r15a
Bak1 Dpp4 Irf8 Plg Tnc Cd74 Socs1 Cdh13 Ptger2
Bank1 Ebi3 Isg15 Pml Tnfaip6 Cd80 Tap1 Cdkn1a Ptgir
Batf2 Eif2ak2 Itga4 Prcp Tnfrsf1a Ciita Tnf Dcbld2 Rcan1
Bcl3 Epsti1 Itgam Prkcd Tnfrsf1b Cmpk2 Tnfaip3 Dusp1 Rgs16
Birc3 F10 Itgb7 Ptafr Tnfrsf21 Cpm Tpbg Edn1 Rsad2
C1qa F5 Junb Ptger4 Tnfsf15 Ctsc Traf1 Egr1 Sele
C1qc F7 Kcnj2 Ptpn1 Tnip2 Dusp2 Trim14 Egr2 Sgk1
C1r Fcer1g Klf2 Ptpn2 Trim25 Dusp6 Tyk2 Ehd1 Timp2
C1s Fcgr1a Kynu Ptpn6 Ube2l6 Ereg Usp18 Fas Tnfaip2
C3ar1 Fjx1 Lamp3 Ptpre Upp1 F2 Vcpip1 Fgl2 Tnfrsf12a
C5ar1 Fos Lcp2 Ptx3 Vcam1 Gpr132 Zfpm2 Fosl2 Tnip1
Casp1 Fosb Lgmn Rel Was Grb2 Znfx1 Gadd45a Trib1
Casp4 Fpr1 Lipa Rhog Zbp1 Gzmk Gp9 Tubb2a
Cblb Gadd45b Lpar1 Ripk1 Zfp36 Herc6 Gpc3 Vamp5
Ccl2 Gch1 Lyn Rnf213 Hla-dma Ier3
Ccl20 Gfpt2 Map3k8 S100a9 Icoslg Ifitm2
Ccl7 Gna15 March1 Samhd1 Ier5 Il10
Ccr1 Gng2 Msr1 Scarf1 Il12b Il15ra
Cd14 Gngt2 Mt2a Scn1b Il13ra1 Il1b
Cd38 Gp1ba Myd88 Sectm1 Il9r Il23a
Cd40 Gpr18 Ncoa3 Sell Irf4 Itga5
Cd44 Gpr183 Nfil3 Selp Irf7 Itih1
Cd48 Gzma Nfkb2 Sema4d Irf9 Jun
Cd83 Hif1a Ninj1 Serpinb2 Kcna3 Klf10
Cd86 Hmox1 Nlrp3 Serpinb8 Klrk1 Klf4
Cebpb Hrh1 Nod1 Serpine1 Lamb3 Lgals3
Cebpd Icam1 Nod2 Serping1 Lck Lgals3bp
Cfb Ido1 Nup93 Sh2b3 Lepr Litaf
Cfh Ifi30 Oas2 Sik1 Lta Ltbr
Chst2 Ifih1 Oas3 Slamf1 Ltb Maff
Clec5a Ifit2 Oasl Slc16a6 Mthfd2 Map2k3
Clu Ifit3 Olr1 Slc28a2 Nfkbia Mcl1
Cntfr Ifngr2 Osm Slc2a6 Nfkbie Mep1a
Col4a2 Il10ra Osmr Socs3 Nlrc5 Mmp12
Cr2 Il10rb P2rx4 Sp110 Peli1 Mmp8
Crlf2 Il17ra P2rx7 Sphk1 Psmb10 Mt3
Csf1 Il18 Panx1 St3gal5 Psmb8 Mvp
Csf2ra Il18bp Parp12 St8sia4 Psmb9 Notch4
Csf2rb Il1a Parp14 Stab1 Rapgef6 Nr4a1
Genes Commonly Enriched in Young DIO vs Young Control 
and Aged Control vs Young Control
Genes Enriched in 
Aged Control vs Young 
Control
Genes Enriched in 





Figure 2.3 Advanced age and DIO induce overlapping alterations in metabolic 
processes within tumor-adjacent mammary adipose. A) Hallmark gene sets 
commonly underrepresented in tumor adjacent mammary adipose tissue of aged control 
vs young control and young DIO vs young control mice determined following gene set 
enrichment analysis (GSEA). B) Leading edge analysis (LEA) of commonly 
underrepresented Hallmark gene sets. C) Frequency of the genes occurring in the 
leading edge of underrepresented gene sets verses gene rank. Significant gene set 
enrichment defined as FDR q-val <0.05. Significance in overlap of leading edge genes 
analyzed using hypergeometric test. Correlation between the gene rank of leading edge 
contributors calculated by the Spearman test. Asterisks denote significance: * < 0.05, ** 





Figure 2.4 Advanced age and DIO enrich the mammary tumor transcriptome for 
protumor signaling. A) Hallmark gene sets commonly enriched in mammary tumor of 
aged control vs young control and young DIO vs young control mice determined 
following gene set enrichment analysis (GSEA). B) Leading edge analysis (LEA) of 
commonly enriched Hallmark gene sets. C) Frequency of genes occurring in the leading 
edge of enriched gene sets verses gene rank. Significant gene set enrichment defined 
as FDR q-val <0.05. Significance in overlap of leading edge genes analyzed using 
hypergeometric test. Correlation between the gene rank of leading edge contributors 





Table 2.3 Hallmark gene set enrichment in mammary tumors from aged control 
mice and young DIO mice, relative to young control.  
 
 
DIO, diet-induced obese; NES, normalized enrichment score; FDR, false discovery rate 
  
NES FDR q-val NES FDR q-val
HALLMARK_INTERFERON_GAMMA_RESPONSE -1.63 0.013 -2.46 < 0.001
HALLMARK_ALLOGRAFT_REJECTION -1.84 0.001 -2.43 < 0.001
HALLMARK_INFLAMMATORY_RESPONSE -1.50 0.028 -1.97 < 0.001
HALLMARK_IL6_JAK_STAT3_SIGNALING -2.08 < 0.001
HALLMARK_INTERFERON_ALPHA_RESPONSE -1.94 < 0.001
HALLMARK_IL2_STAT5_SIGNALING -1.87 < 0.001
HALLMARK_TGF_BETA_SIGNALING 1.42 0.045
HALLMARK_COAGULATION 1.64 0.007
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 2.31 < 0.001 2.16 < 0.001
HALLMARK_ANGIOGENESIS 1.73 0.004 1.50 0.016
HALLMARK_MYOGENESIS -2.52 0.000 -1.72 0.002
HALLMARK_GLYCOLYSIS 1.68 0.006
HALLMARK_OXIDATIVE_PHOSPHORYLATION -1.57 0.019
HALLMARK_E2F_TARGETS 1.63 0.006 1.99 0.001
HALLMARK_MITOTIC_SPINDLE 2.02 < 0.001 1.92 < 0.001
HALLMARK_G2M_CHECKPOINT 1.71 0.003 1.75 0.003
HALLMARK_MYC_TARGETS_V1 1.63 0.008




HALLMARK_APICAL_JUNCTION 1.98 < 0.001 1.61 0.008
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Figure 2.5 Advanced age and obesity promote immunosuppression within the 
tumor microenvironment and decreased CD8 T cell surveillance. A) Hallmark gene 
sets commonly underrepresented in mammary tumors of aged control vs young control 
and young DIO vs young control mice determined following gene set enrichment 
analysis (GSEA). B) Leading edge analysis (LEA) of commonly underrepresented 
immune-related Hallmark gene sets. C) Frequency of the genes occurring in the leading 
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edge of underrepresented gene sets verses gene rank. D) C7 Immunologic gene sets 
commonly underrepresented in mammary tumor of aged control vs young control and 
young DIO vs young control mice were determined following GSEA. E) LEA of 
commonly underrepresented C7 gene sets. F) Frequency of the genes occurring in the 
leading edge of underrepresented gene sets verses gene rank. G) Heat map of select 
leading edge genes. H-I) Percentage of cells stained positively by 
immunohistochemistry for CD3 (H) and CD8 (I) analyzed using QuPath. Significant 
gene set enrichment defined as FDR q-val <0.05. Significance in overlap of leading 
edge genes analyzed using hypergeometric test. Correlation between the gene rank of 
leading edge contributors calculated by the Spearman test. IHC quantification presented 
as mean ± SD analyzed relative to young control using one-way ANOVA and Dunnet 




Table 2.4 Leading edges of immune-related gene sets underrepresented in 
mammary tumors of aged control and young DIO mice vs young control. 
  
Enriched in Aged 
Control vs Young 
Control
Ache Ciita Il4r Sectm1 Best1 Aplnr Npffr2
Adora2b Cmklr1 Il7r Sele Cdkn2a Arl4a P2rx4
Apol6 Csf2rb Irak2 Sell Crtam Bank1 P2ry14
Aqp9 Csf3r Irf4 Selp Eif3j C1r Pde4b
Auts2 Cxcl11 Irf5 Sit1 Fpr1 C1s Pdpn
Batf2 Cxcl9 Irf8 Slamf1 Hdac9 Casp7 Peli1
Btg2 Cxcr3 Isg20 Slamf7 Igsf6 Ccl19 Pik3r5
Casp1 Cxcr6 Itgb2 Slc11a2 Il4 Ccl2 Pnp
Casp4 Ebi3 Itk Slc1a2 Krt1 Ccl24 Psmb10
Ccl11 Epsti1 Kcna3 Slc28a2 Mep1a Ccr5 Psmb9
Ccl17 Faslg Kcnj2 Socs3 Mettl7b Cfb Psme2
Ccl22 Fcgr1a Klrd1 Sp110 Osm Clec5a Ptprc
Ccl4 Ffar2 Klrk1 St8sia4 Prok2 Cxcl10 Rnf144b
Ccl5 Fgl2 Lck Stat4 Slc31a2 Cxcl13 Rsad2
Ccl7 Fgr Lcp2 Tlr1 Sspn Cybb Samd9l
Ccr1 Gna15 Ltb Tnf Tnfsf9 Ddx60 Samhd1
Ccr2 Gpr132 March1 Tnfaip3 Tor1b Fas Sema4d
Ccr7 Gpr18 Map4k1 Tnfsf10 Fyb Slc25a28
Ccrl2 Gzma Mefv Tnfsf15 Gpr183 Slc4a4
Cd2 Hla-dma Msr1 Trat1 Gpr65 Slc7a2
Cd247 Hla-dmb Mxd1 Trim14 Hcls1 Socs1
Cd274 Hla-doa Myd88 Vamp5 Ifi35 Stat2
Cd28 Icam1 Ncf4 Vamp8 Ifit2 Tacr1
Cd3d Icam4 Nod1 Was Il12a Tap2
Cd3e Icoslg Nod2 Zap70 Il15 Thy1
Cd3g Ido1 Oas3 Il18 Tlr2
Cd4 Ifi30 Oasl Il18bp Tlr6
Cd40 Ifng P2ry2 Il2rg Trafd1
Cd40lg Ikbkb Pim1 Il6 Trim21
Cd48 Il10 Prf1 Il7 Trim26
Cd55 Il10ra Ptafr Irf1 Txnip
Cd69 Il12b Ptger2 Irf2 Zbp1
Cd7 Il12rb1 Ptger4 Isg15
Cd70 Il15ra Ptgir Itgal
Cd74 Il16 Ptpn6 Jak2
Cd79a Il18r1 Rasgrp1 Lyn
Cd86 Il1b Rgs1 Ncr1
Cd8a Il27ra Rnf31 Nlrc5
Cd8b Il2ra Rpl3l Nlrp3
Cd96 Il2rb Scn1b Nmi
Genes Commonly Enriched in Young DIO vs Young 
Control and Aged Control vs Young Control





Figure 2.6 MetM-WNTlung tumor growth is constrained by CD8 immune 
surveillance. A) Study Schematic and In vivo tumor growth monitored by caliper 
measurement of tumor length (L), the greatest diameter, and width (W), the diameter 
perpendicular to the L, and the equation V=L x W2 x 0.5. B-E) Flow cytometric analysis 
of splenic and tumoral CD45+CD3+CD8+ T cell populations at interim timepoint and 
study end point.  (F-G) Flow cytometric analysis of splenic and tumoral CD45+CD8+ 
cells at study endpoint. H-K) Ex vivo tumor mass measured days 13, 17, 21, and 25 
following tumor injection. Data presented as mean ± SD. Differences across three 
groups analyzed using one-way ANOVA and Tukey post hoc test. Statistical differences 
across two groups determined by t test. Asterisks denote significance: * p< 0.05, ** p< 
0.01, *** p< 0.001. 
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Figure 2.7 The combination of DIO with advanced age promoted greater tumor 
burden in aged DIO mice compared with aged control. A) Study schematic. B) Body 
weight at tumor inoculation. C) % body fat mass and D) % lean mass measured at study 
endpoint. E) In vivo tumor growth monitored by caliper measurement of tumor length 
(L), the greatest diameter, and width (W), the diameter perpendicular to the L, and the 
equation V=L x W2 x 0.5. F) Percentage of mice that developed palpable mammary 
tumors analyzed using Fisher’s exact test. G) Ex vivo tumor mass. H) Percentage of 
mice bearing lung metastases analyzed using Fisher’s exact test. Data presented as 
mean ± SD. Differences across groups analyzed using one-way ANOVA and Tukey 
post hoc test, unless otherwise specified. Asterisks indicate differences in significance. * 





Figure 2.8 The combination of advanced age and DIO exacerbates tumor immune 
suppression. A-E) Cytokines measured in serum collected at an interim timepoint, prior 
to tumor inoculation. F) Hallmark gene sets commonly enriched and underrepresented 
in mammary tumor of aged DIO vs aged control mice determined using gene set 
enrichment analysis (GSEA). Significantly threshold set to FDR q-val <0.05. G) Heat 
map of select leading edge genes. Data presented as mean ± SD. Differences across 
groups analyzed using one-way ANOVA and Tukey post hoc test, unless otherwise 
specified. Asterisks indicate differences in significance. * p < 0.05., ** p < 0.01, *** p < 
0.001.  
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Table 2.5 Hallmark gene set enrichment in mammary tumors from aged DIO mice 
vs aged control.  
 
 
DIO, diet-induced obese; NES, normalized enrichment score; FDR, false discovery rate 
NES FDR q-val
HALLMARK_INTERFERON_ALPHA_RESPONSE -2.32 < 0.001
HALLMARK_ALLOGRAFT_REJECTION -2.20 < 0.001
HALLMARK_INTERFERON_GAMMA_RESPONSE -2.10 < 0.001
HALLMARK_TNFA_SIGNALING_VIA_NFKB -1.47 0.030
HALLMARK_INFLAMMATORY_RESPONSE -1.42 0.037
HALLMARK_ADIPOGENESIS 2.10 < 0.001
HALLMARK_MYOGENESIS 2.09 < 0.001
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 2.07 < 0.001
HALLMARK_ANGIOGENESIS 1.68 0.003
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Table 2.6 Leading edges of immune-related gene sets underrepresented in 
mammary tumors of aged DIO vs aged control. 
Adar Cx3cl1 Ifit3 Msc Stat1
Apbb1 Cxcl10 Ikbkb Mthfd2 Stat2
Aplnr Cxcl11 Il10ra Ncr1 Stat4
Aqp9 Cxcl9 Il12b Nfkbie Tacr1
Bank1 Cxcr3 Il12rb1 Nlrc5 Tlr1
Batf2 Cxcr6 Il13 Nmur1 Tnc
Bcl2a1 Ddx58 Il15 Nod1 Tnf
Bmp2 Ddx60 Il18bp Nod2 Tnfaip3
Brca1 Dhx58 Il1a Npffr2 Tnfsf10
C2 Dusp2 Il1b Nr4a3 Tnfsf15
Ccl19 Ebi3 Il23a Oas1 Traf1
Ccl22 Egr3 Il2ra Oas2 Traf2
Ccl4 Eif2ak2 Il2rb Oas3 Trafd1
Ccl5 Epsti1 Il4 Oasl Trat1
Ccnd2 F2 Il7 Oprk1 Trim14
Ccr5 Faslg Il7r Parp12 Trim21
Ccr7 Fgr Il9 Parp14 Trim26
Ccrl2 Fut4 Irf1 Phlda2 Trim5
Cd274 Gadd45b Irf4 Plau Uba7
Cd3d Gem Irf7 Pml Usp18
Cd3e Gpr132 Irf9 Prf1 Zap70
Cd3g Gpr18 Isg15 Psmb10 Zbp1
Cd4 Gpr183 Itgal Psmb9 Znfx1
Cd40 Gzma Itk Ptafr
Cd40lg Gzmb Kcna3 Ptpn6
Cd69 Herc6 Kcnmb2 Ptprc
Cd7 Hla-dma Klrd1 Rasgrp1
Cd74 Hla-dmb Klrk1 Rgs16
Cd80 Hla-dob Kynu Ripk2
Cd83 Icam1 Lamb3 Rnf213
Cd86 Icoslg Lamp3 Rnf31
Cd8a Ido1 Lck Rsad2
Cd8b Ifi35 Lif Rtp4
Ciita Ifi44 Ltb Sema4d
Cmpk2 Ifi44l Map4k1 Slamf7
Csf2 Ifih1 Mefv Slc2a6
Csf3r Ifit2 Mettl7b Sp110
Enriched in Aged DIO vs Aged Control
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CHAPTER 3. WEIGHT LOSS BY CALORIE RESTRICTION INTERVENTIONS 
ATTENUATE TUMOR IMMUNOSUPPRESSION AND MAMMARY TUMOR GROWTH 
IN OBESE, AGED, AND AGED OBESE MICE 
Background 
Breast cancer (BC) is the second deadliest cancer among US women169. In 
2020, approximately 115 women are predicted to die of BC every day169. Over 70% of 
BC-related deaths occur in patients aged 60 years and older170. Additionally, BC patient 
with obesity, regardless of menopausal status, exhibit poorer overall and BC-specific 
survival14. The clear impact of advanced age and obesity on BC mortality poses a major 
public health concern for our aging population that is increasingly burdened by 
obesity12,13,23. Interventions that reduce BC risk in patients with advanced age and/or 
obesity are urgently needed.  
We previously demonstrated that advanced age and obesity drive mammary 
tumor growth, in part, through tumor immunosuppression (Chapter 2). Specifically, 
tumors from aged control and young DIO mice, compared with young control mice, 
exhibit reduced abundance of CD8 T cells and suppression of transcripts relating to 
antitumor immunity. These findings are significant because the host immune system 
plays a critical role in controlling tumorigenesis41. A successful antitumor immune 
responses involves multiple carefully orchestrated interactions between tumor cells and 
the host immune system that ultimately results in optimal priming of cytotoxic CD8 T 
cells and their migration into the tumor bed41. Once in the tumor bed, CD8 T cell 
detection of tumor cells and activation of co-stimulatory pathways results in the release 
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of cytotoxic effector molecules capable of killing the cancerous cells41. However, tumors 
and other cells within the microenvironment can elicit a variety of immunosuppressive 
signaling pathways to reduce antitumor immune responses and sustain BC 
progression41,53,75. Further, immunosuppression in human breast tumors, characterized 
by reduced tumor-infiltrating lymphocytes or CD8 T cells, is associated with poor patient 
outcomes57,58. Given the critical role of the immune system in controlling cancer 
progression and our findings that advanced age and obesity induce tumor 
immunosuppression, we hypothesized that dietary interventions effective in reducing 
age- and/or obesity-associated tumor burden mitigate tumor immunosuppression. 
Dietary interventions that reduce tumorigenesis in preclinical models are chronic 
calorie restriction (CCR) and intermittent fasting. CCR, which involves daily 10-30% 
calorie restriction, exerts anticancer effects in preclinical models by reducing incidence, 
increasing latency, and slowing growth of mammary tumors22,95,97. Antitumorigenic 
effects of CCR are attributed to multiple mechanisms, including reductions in: systemic 
growth factors and adipokines, such as insulin, IGF-1, and leptin; mitogenic substrates 
for cancer cell proliferation, such as glucose and fatty acids; and decreased 
inflammation95. In addition, CCR attenuates advanced age- and obesity-related declines 
in T cell function107-109 and enhances tumor immune surveillance in lean, tumor-bearing 
mice98. Intermittent fasting regimens, which consist of reoccurring periods (e.g. 16-48 
hours) of low to no calorie consumption, decrease tumor incidence and slows tumor 
growth in preclinical models96,114,171. Mechanistically, intermittent fasting regimens result 
in favorable modulation of metabolic and inflammatory mediators, similar to that 
observed in CCR114,171. Additionally, short-term intermittent fasting implemented 
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adjuvant to chemotherapeutic agents enhanced CD8 T cell infiltration and cytotoxicity in 
mammary tumors127.  
We are particularly interested in the 5:2 diet, an intermittent fasting regimen 
being examined as primary prevention strategy for BC in overweight and obese 
patients119,172. The 5:2 diet involves 5 days/week of a healthy diet, such as the 
Mediterranean diet, with two consecutive days of a low calorie, low carbohydrate 
diet119,172. Clinical trials have shown that the 5:2 diet is as effective as, if not superior to, 
CCR in reducing weight and improving serum levels of metabolic and inflammatory 
mediators in overweight and obese individuals119. 
In a recent study, we tested whether placement of diet-induced obese (DIO) mice 
on one of three dietary interventions would resolve DIO-related acceleration of 
mammary tumor growth. The three dietary interventions examined were 1) a low-fat 
(LF) diet provided ad libitum, 2) 30% chronic calorie restriction (CCR), and 3) 
intermittent calorie restriction diet modeled after the 5:2 diet (ICR)119,172. Results from 
this study indicated that placement of DIO mice on the CCR and ICR regimen reduced 
mammary tumor mass compared to DIO mice that remained on the DIO diet provided 
ad libitum (unpublished data, Bowers, et al.). In addition, tumors from CCR and ICR 
mice weight significantly less than that of control-fed mice that had never been obese 
(unpublished data, Bowers, et al.). In contrast, DIO mice placed on a (LF) diet, provided 
ad libitum, did not have differential tumor burden compare to DIO mice (unpublished 
data, Bowers LW et al.).  
Given efficacy of CCR and ICR in attenuating obesity-associated tumor growth 
and reported immune modulatory effects of CCR and other IF regimens, we 
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hypothesized that CCR and ICR resulted in reversion of obesity-associated tumor 
immunosuppression. Using samples from the study conducted by Bowers and 
colleagues we examined if either CCR, ICR or LF dietary interventions reversed DIO-
associated suppression of transcription related to antitumor immunity. DIO mice 
switched to either ICR or CCR, but not a LF diet, displayed mitigation of obesity-related 
tumor immunosuppression. We next tested whether calorie restriction interventions 
would provide the same benefit in aged and aged obese mice. Since both CCR and ICR 
provided comparable benefit in the first study, we chose to utilize ICR in this second 
study as it may be easier for patients to adhere to than a chronic restriction. ICR 
intervention in aged, obese, and aged obese mice significantly reduced body weight, 
decreased mammary tumor growth, and enhanced immune-related transcription within 
the tumor microenvironment. These data indicate that calorie restriction interventions 
reverse the adverse effects of advanced age, obesity, and the combination of advanced 




All animal protocols were approved by the University of North Carolina at Chapel 
Hill Institutional Animal Care and Use Committee (IACUC) and carried out in 
compliance with all guidelines and regulations. 
Dietary weight loss interventions in young obese mice: Female, 6-8 week-old 
C57BL/6 mice were purchased from Charles River Laboratories, Inc. (Wilmington, MA). 
Mice were housed 2 per cage and randomized to receive 1 of 2 diets, both fed ad 
libitum: control low-fat (control; n=20; 10% kcal from fat; catalog #D12450J, Research 
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Diets, Inc.) or diet-induced obesity (DIO; n=60; 60% kcal from fat; catalog #D12492, 
Research Diets, Inc.). After 15 weeks on diet, mice receiving the control diet continued 
on that regimen ad libitum for the remainder of the study (Control), while those receiving 
the DIO regimen were further randomized to 3 diet groups (n=20/group): 1) remain on 
DIO ad libitum (DIO), or change to 2) control diet ad libitum (LF), 3) 30% chronic calorie 
restricted (CCR) diet or 4) intermittent calorie restricted (ICR) diet. The ICR regimen 
consisted of a 14% calorie-restricted (CR) diet for 5 nonconsecutive days/week and a 
70% CR, high-protein diet on the remaining 2 days/week. The ICR diet composition and 
schedule were modeled after the “intermittent energy and carbohydrate restriction” diet 
utilized by Harvie and colleagues in randomized controlled trials119,172. Following 10 
weeks of dietary intervention, mice received orthotopic mammary injection with E0771 
mammary tumor cells (3.5 x 104 cells/50 μL PBS). Mice were monitored until they 
reached tumor endpoint, defined as the majority of mice within one experimental group 
having tumors reach 1.5 cm diameter in any direction. At tumor endpoint, mice were 
euthanized, tumors excised and weighed, and other tissues collected for molecular 
analyses, including serum and lungs.   
ICR in aged, obese, and aged obese mice: Cohorts of young (2 mo.; n=60) and 
aged (12 mo.; n=68) mice purchased from The Jackson Laboratory (Bar Harbor, ME) 
were housed 5 per cage and randomized to receive 1 of 2 diets, both fed ad libitum: 
control low-fat (control; n=20; 10% kcal from fat; catalog #D12450J, Research Diets, 
Inc.) or diet-induced obesity (DIO; n=100; 60% kcal from fat; catalog #D12492, 
Research Diets, Inc.). After 15 weeks on diet, mice were singly housed and block 
randomized, based on body weight, to either remain on their respective diets or change 
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to the ICR regimen described above. Levels of restriction were based on the 
consumption of aged-matched, control-fed cohorts. Nine weeks following ICR initiation 
mice were orthotopically injected in the 4th mammary fat pad with E0771 mammary 
tumor cells (3.5 x 104 cells/50 μL PBS). In vivo tumor growth was monitored twice 
weekly with digital calipers, until tumor end point as defined above. At tumor endpoint, 
mice were euthanized, tumors excised and weighed, and other tissues collected for 
molecular analyses, including serum and lungs.  
Body composition measures 
Body composition was measured via quantitative magnetic resonance imaging 
(Echo Medical Systems, Houston, TX) prior to tumor inoculation and at endpoint. 
Imaging resulted in measurements of lean mass, fat mass and total water mass. 
Percent body fat mass and lean mass was calculated by dividing fat mass or lean mass, 
respectively, by total body weight. 
RNA profiling and gene set enrichment analysis (GSEA) 
RNA was isolated from flash-frozen mammary tumors using TRIzol Reagent 
(Sigma-Aldrich) and RNeasy Mini Kit (Qiagen) according to manufacturer's instructions. 
Adjacent mammary and matched tumor samples were selected from mice with tumor 
masses closest to the median of their experimental group (n=6/group).  RNA quality was 
assessed using an Agilent 2100 Bioanalyzer. GeneChip WT PLUS Reagent Kit was 
used to synthesize fragmented and labeled sense-strand cDNA from total RNA (250 ng) 
according to the manufacturer’s protocol. Fragmented and labeled cDNA was used to 
prepare a hybridization cocktail with the Affymetrix GeneTitan Hybridization Wash and 
Stain Kit for WT Arrays. Hybridization, washing, staining and scanning of the Affymetrix 
Gene Chip Mouse Genome 430 2.0 Array was carried out using the Affymetrix 
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GeneTitan MC Instrument. Transcriptome Analysis Console Software v 4.0 was used 
for quality control and differential gene expression analysis. Significantly differentially 
expressed genes were defined by fold-change cut off of >1.5 and FDR q-value <0.05. 
Bulk gene expression data was analyzed using GSEA in combination with 
Hallmark gene sets150,151. Significantly enriched gene sets across pair-wise 
comparisons were defined as having FDR q-value < 0.05. Gene sets commonly 
enriched were identified and leading edge analysis performed on overlapping gene 
sets150,151. The probability of overlapping leading edges was computed via 
hypergeometric analysis.  
Statistical analyses 
Animal study data are presented as mean ± SD and were analyzed using 
GraphPad Prism software (GraphPad Software Inc.), and statistically significant 
differences were defined by p <0.05. Differences across four experimental groups were 
analyzed using one-way ANOVA, followed by Tukey post hoc test. Data from 
experiments with three independent variables (e.g. age, baseline diet, and intervention) 
were analyzed using three-way ANOVA, followed by Tukey post hoc test. 
Results 
Calorie restriction dietary interventions reverse obesity-related mammary tumor 
immunosuppression 
Given our previous observation that CCR and ICR interventions attenuate tumor 
progression in formerly obese mice along with the existing literature demonstrating that 
calorie restriction interventions enhances tumor immune surveillance in lean 
mice98,108,127, we hypothesized that CCR and ICR would reverse obesity-associated 
tumor immunosuppression. To test our hypothesis, we profiled gene expression from 
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mammary tumor samples collected in the study conducted by Bowers and colleagues 
(Figure 3.1A). Differential gene expression was analyzed using Transcriptome Analysis 
Software (TAC; ThermoFisher Scientific) across the following pair-wise comparisons: 1) 
DIO vs control, 2) LF vs control, 3) CCR vs control, and 4) ICR vs control. Relatively few 
genes were differentially expressed, as defined by fold-change cut off of >1.5 and FDR 
q-value <0.05, in tumors of DIO mice compared with control (2 genes up-regulated and 
3 down-regulated) and no genes were differentially expressed in tumors of LF mice 
compared with control (Figure 3.1B). In contrast, tumors from CCR mice differentially 
expressed 204 genes relative to control (82 upregulated and 122 downregulated) 
(Figure 3.1B-C). Upregulated genes in CCR tumors, relative to control, included those 
encoding cytotoxic granzymes (i.e. Gzmb, Gzmc, Gzmd, Gzme, Gzmf, and Gzmg) and 
perforin (Prf1) (Figure 3.1C). Tumors from ICR mice had 615 differentially expressed 
genes relative to control (107 upregulated and 508 downregulated) (Figure 3.1D). 
Upregulated genes in ICR tumors, relative to control, included those relating to immune 
activation (e.g. immune checkpoints Ctla4, Havcr2, and, Icos) (Figure 3.1D). 
Due to the limited number of gene-level changes that passed the defined 
significance threshold in DIO vs control, we could not adequately assess the impact of 
DIO on tumor transcriptomics and consequently whether CCR or ICR reversed DIO-
related effects. Therefore, we performed GSEA using Hallmark gene sets to discern if 
modest and coordinated transcriptional changes were occurring within the tumor 
microenvironment that reflect enrichment for specific pathways or processes. We first 
compared tumors from DIO and control mice and identified underrepresentation of 10 
Hallmark gene sets (Figure 3.2A; Table 3.1). Consistent with previous observations of 
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DIO-related tumor immunosuppression, six of the underrepresented gene sets were 
immune- or inflammatory-related (e.g. interferon alpha (IFNA) response, interferon 
gamma (IFNG) response, and inflammatory response) (Figure 3.2A; Table 3.1). We 
also observed enrichment for 11 Hallmark gene sets in tumors from DIO mice compared 
with control (Figure 3.2B; Table 3.1). Enriched gene sets included those related to 
developmental processes (e.g. adipogenesis and angiogenesis), metabolism (e.g. fatty 
acid metabolism and glycolysis), as well as, epithelial mesenchymal transition, a 
process implicated in metastatic progression (Figure 3.2B; Table 3.1)153. 
To determine if either dietary weight loss intervention reversed DIO-associated 
suppression of immune related transcription, we performed GSEA with Hallmark gene 
sets comparing each weight loss intervention group to control (Figures 3.3A-B). 
Tumors from LF mice were enriched for 7 gene sets and underrepresented for 5 gene 
sets, relative to control (Figures 3.3A-B; Table 3.1). Three of the underrepresented 
gene sets in tumors from LF mice vs control were immune-related and were also 
underrepresented in tumors of DIO mice vs control (i.e. IFNG response, IFNA response, 
and allograft rejection) (Figures 3.3A; Table 3.1). Tumors from CCR mice were 
underrepresented for 4 gene sets and enriched for 2 gene sets compared with control 
(Figures 3.3A-B; Table 3.1). Tumors from ICR mice were underrepresented for 2 gene 
sets and enriched for 3 gene sets relative to control (Figures 3.3A-B). Contrasting our 
observation that immune-related gene set were underrepresentation in tumors from LF 
and DIO mice, relative to control, two immunologic gene sets were enriched in tumors 
from CCR and ICR mice, relative to control (i.e. inflammatory response and allograft 
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rejection) (Figures 3.3A-B), indicating enhanced immune-related signaling compared 
with control.  
Next we performed leading edge analysis on immune-related gene sets mutually 
underrepresentation in DIO and LF vs control and enriched in CCR and ICR vs control. 
Leading edges that contributed to underrepresentation of immune related gene sets in 
DIO vs control and LF vs control overlapped significantly (Figure 3.3C). Commonly 
underrepresented leading edge genes included those relating to antigen presentation 
and co-stimulation, T cell receptor (TCR) signaling, and cytotoxic effector function 
(Figure 3.3D; Table 3.2). Leading edges that contributed to enrichment of immune-
related gene sets in CCR vs control and ICR vs control demonstrated significant overlap 
(Figure 3.3E). Commonly enriched leading edge genes were relating to TCR signaling 
and cytotoxic effector function (Figure 3.3F; Table 3.2).  
Development of lean and obese phenotypes in young and aged mice 
Only calorie restriction interventions were successful at reversing obesity-related 
tumor immune suppression in young mice. To determine whether calorie restrictive 
interventions provide the same benefit to aged and aged obese mice, cohorts of young 
and aged mice were placed on either the low-fat control or high-fat DIO diet for 15 
weeks to generate normoweight and obese phenotypes, respectively (Figure 3.4A). 
Body weight, % body fat, and % lean mass composition were measured by qMR to 
confirm development of normoweight and obese phenotypes. As expected, DIO feeding 
resulted in significantly increased body weight and % body fat composition (percentage 
of body fat mass relative to total body weight) compared with aged-matched, control-fed 
counterparts (Figures 3.4B-C). Advanced age increased total body weight and percent 
body fat composition in aged control relative to young control mice (Figures 3.4B-C). 
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Body weight did not differ between young DIO and aged control mice; however, young 
DIO had increased % body fat composition (Figures 3.4B-C). The combination of 
advanced age and DIO resulted in the greatest body weight and % body fat composition 
(Figures 3.4B-C).  Lean mass composition (percentage of lean mass relative to total 
body weight) descended across all experimental groups in following order: young 
control, aged control, young DIO, aged DIO (Figure 3.4D).  
ICR implementation reduces body weight and diminishes tumor growth in young 
DIO, aged control, and aged DIO mice 
 The ICR intervention consisted of 70% CR on 2 nonconsecutive days per week 
and 14% CR the remaining 5 days per week, and provided a net 30% calorie reduction 
each week (Figure 3.4A). To determine the amount of ICR diet to provide, intake was 
measured in ad libitum-fed mice over a three week period. Daily food intake did not 
differ between aged-matched groups (i.e. young control vs young DIO or aged control 
vs aged DIO); however, daily food intake was significantly greater in aged mice 
compared with young mice (Appendix II). This resulted in increased kilocalorie 
consumption in aged control vs young control and aged DIO vs young DIO mice (Figure 
3.4E). We also noted that due to greater caloric density in the high-fat, DIO diet, DIO-
fed mice consumed increased kilocalories per day relative to control-fed, aged-matched 
cohorts (Figure 3.4E). To determine whether differences in energy consumption were 
reflective of increased body mass, we calculated daily energy intake relative to body 
weight. There was no difference in daily energy consumption relative to body weight 
between young control, aged control, or aged DIO cohorts (Figure 3.4F). In contrast, 
young DIO mice had significantly greater energy intake relative to body weight (Figure 
3.4F). These data demonstrate increased caloric intake in aged control compared with 
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young control mice, but not relative to body weight. Therefore, we implemented two 
different levels of ICR, one based on energy consumption of young control mice to be 
implemented in both young cohorts and a second based on energy consumption of 
aged control mice to be implemented in both aged cohorts. 
 Following 15 weeks on control or DIO diets, mice were randomized to either 
remain on their current baseline diet or switch to the ICR intervention (Figure 3.4A). 
Nine weeks after diet switch, body weight measurements were analyzed to assess 
extent of ICR-induced weight loss. Among mice that had remained on their baseline 
diets provided ad libitum, body weight increased across all experimental groups in 
following order: young control, aged control, young DIO, aged DIO (Figure 3.4G). ICR 
intervention resulted in significantly decreased body weight in young control ICR, young 
DIO ICR, aged control ICR, and aged DIO ICR compared with respective aged-matched 
and baseline diet-matched comparators (Figure 3.4G). In addition, ICR implementation 
resulted in body weight that was equivalent to (i.e. aged control ICR and aged DIO ICR) 
or less than (i.e. young control ICR and young DIO ICR) that observed in young control 
mice (Figure 3.4G). Unfortunately, we were unable to measure body composition at this 
timepoint due to COVID-19 research restrictions.  
To test whether ICR inhibited mammary tumor growth, mice received mammary 
injection with basal-like E0771 mammary carcinoma cells and were followed to tumor 
endpoint (Figure 3.5A). In accordance with our previous findings, tumors from DIO-fed 
mice had significantly greater mass at endpoint compared with aged-matched control-
fed mice (Figure 3.5B). There was no difference in tumor burden with advanced age 
alone (i.e. aged control vs young control); however, the combination of advanced age 
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and DIO resulted in the greatest tumor mass in aged DIO mice relative to all other 
groups (Figure 3.5B). Tumor mass was significantly reduced in young DIO ICR, aged 
control ICR, and aged DIO ICR mice compared with aged-matched and baseline diet-
matched comparators (Figure 3.5B). In addition, tumor mass observed in ICR treated 
mice did not statistically differ from that of young control ad libitum-fed mice (Figure 
3.5B).  
ICR attenuates tumor immunosuppression in young control, young DIO, aged 
control and aged DIO mice 
To assess the effects of advanced age, obesity, and the combination of 
advanced age and obesity on the immune contexture within the tumor 
microenvironment, mammary tumor gene expression was analyzed using GSEA and 
Hallmark gene sets. Three pair-wise comparisons were made: young DIO vs young 
control, aged control vs young control, and aged DIO vs young control. We observed 
significant enrichment for 6 gene sets in young DIO vs young control (all 
underrepresented), 7 gene sets in aged control vs young control (all underrepresented), 
and 7 gene sets in aged DIO vs young control (3 enriched and 4 underrepresented) 
(Table 3.3). Three immune-related gene sets were underrepresented across all three 
comparisons (i.e. IFNG response, IFNA response, and allograft rejection) (Figure 3.7A; 
Table 3.3). Additional immunologic gene sets were underrepresented in tumors from 
young DIO mice relative to control (i.e. IL6/JAK/STAT3 signaling) and aged control mice 
relative to control (i.e. IL6/JAK/STAT3 signaling, IL2/STAT5 signaling, and inflammatory 
response. 
Given that aged DIO mice had the greatest tumor burden relative to all other 
experimental groups, including aged control and young DIO, we hypothesized that the 
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combination of advanced age and obesity resulted in greater tumor immunosuppression 
compared with advanced age or obesity alone. To assess, GSEA was performed across 
the following pairwise comparisons: aged DIO vs aged control and aged DIO vs young 
DIO. We observed enrichment for 8 hallmark gene sets (all enriched) when comparing 
aged DIO versus aged control and 18 sets (17 enriched and 1 underrepresented) when 
comparing aged DIO vs young DIO (Table 3.4). Tumors from aged DIO mice were 
enriched for immune-related gene sets compared with both young DIO and aged control 
(Figure 3.7B; Table 3.4). Additional gene sets enriched in aged DIO relative to both 
young DIO and aged control included those relating to epithelial mesenchymal transition 
and angiogenesis, processes associated with tumor aggression (Figure 3.7B; Table 
3.4). 
 Given the antitumor effects with ICR intervention, we next asked whether ICR 
attenuated tumor growth, in part, through reversal of tumor immunosuppression in aged, 
obese, and aged obese mice. To address this, we performed GSEA across the 
following three pair-wise comparisons: young DIO ICR vs young DIO, aged control ICR 
vs aged control, and aged DIO ICR vs aged DIO. We observed enrichment for 22 gene 
sets in young DIO ICR vs young DIO (all enriched), 9 gene sets in aged control ICR vs 
aged control (7 enriched and 2 underrepresented), and 7 in aged DIO ICR vs aged DIO 
(5 enriched and 2 underrepresented) (Table 3.5). Across comparisons, we observed 
enrichment for immune-related gene sets indicating that ICR enhances immune 
signaling in young control mice and reverses tumor immunosuppression in young DIO, 




  Advanced age and obesity significantly increase a woman’s risk of developing 
and dying from BC14,170, which is the most commonly diagnosed and second deadliest 
cancer among US women169.  In the previous chapter, we found that advanced age and 
obesity enhanced mammary tumor growth, in part, through overlapping patterns of 
tumor immunosuppression. We initially tested the effects of three dietary interventions in 
obese mice and found that CCR and ICR, but not LF diet, reversed obesity-associated 
tumor immunosuppression. Tumors from CCR- and ICR-treated mice were also 
enriched in immune signaling-related gene signatures when compared with control mice 
that had never been obese. Given similar success of the two calorie restriction 
interventions, we tested whether caloric restriction provided the same effects in aged 
and aged obese mice. Specifically, we tested the effects of ICR as this intervention 
might be easier for patients to adhere than chronic restriction and thus would be more 
translatable. In confirmation of obesity- and age-related tumor immunosuppression, 
tumors from young DIO, aged control, and aged DIO mice, compared with young control 
mice, exhibited suppression of immune-related transcripts. Implementation of ICR 
reversed tumor immune suppression and attenuated mammary tumor progression in 
young DIO, aged control, and aged DIO mice. 
In young DIO mice, weight loss by a LF diet does not reduce tumor burden, 
compared with mice that remained on DIO diet. Furthermore, tumors from LF mice, 
compared with controls, and DIO mice, compared with controls, mutually 
underrepresent three immune-related gene sets (i.e. IFNG response, IFNA response, 
and allograft rejection) indicating that obesity-associated tumor immunosuppression 
persists in formerly-obese mice that lost weight via LF diet. Comparison of leading 
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edges that contributed to underrepresentation of IFNG response, IFNA response, and 
allograft rejection in LF vs control and DIO vs control revealed significant overlap. 
Commonly underrepresented leading edge genes were relating to many steps within the 
antitumor immune response including antigen presentation and stimulation, TCR 
signaling, and cytotoxic effector function. In addition to receptors found on CD8 T cells 
(i.e. Cd3d, Cd3G, and CD8a), chemokines associated with T cell infiltration (i.e. Ccl5, 
Cxcl9, and Cxcl11) and cytotoxic effector molecules secreted by CD8 T cells (i.e. Prf1 
and Gzma) were underrepresented in tumors of DIO and LF mice compared with 
control, signifying reduced infiltration and activation of CD8 T cells44,59,60. In Chapter 2 
we demonstrated that DIO in young mice reduced tumoral abundance of CD8 positive 
cells; additional analyses are underway testing whether underrepresentation of CD8 T 
cell-related transcripts in this study translates to reduced CD8 T cell abundance in DIO 
and LF compared with control tumors. Based on the evidence thus far, we conclude that 
weight loss by a LF diet provided ad libitum fails to completely reverse obesity-
associated tumor immunosuppression. 
Clinical studies investigating the impact of LF diet on BC outcomes have 
produced conflicting results. The Women’s Health Initiative trial, a large randomized 
clinical trial with nearly 50,000 postmenopausal women, found that LF eating patterns 
implemented in women with no history of BC had no effect on BC incidence; however, 
participants on the LF intervention experienced reduced mortality rates after BC 
diagnosis139.  In the Women’s Intervention Nutrition Study, a LF diet regimen in patients 
with early-stage BC increased relapse-free survival, with greater effects seen in patients 
with estrogen receptor negative tumors140. In contrast, the Women’s Healthy Eating and 
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Living trial, which also enrolled early stage BC patients, found no reduction disease 
recurrence or mortality with LF diet141, unless the analysis was limited to subjects 
without post-treatment hot flashes142. A weight loss intervention trial conducted by 
Fabian, et al. found that substantial weight loss of >10% was necessary to see 
consistent reduction in BC risk biomarkers104,105. While LF diet-fed mice in our study lost 
on average greater than 10% of their peak body weight, the weight loss intervention did 
not return body weights to levels observed in control mice at tumor inoculation (data not 
shown; Bowers, et al, Unpublished). The success of LF diet interventions for BC 
prevention and treatment outcomes may be influenced by total weight loss by dietary 
intervention, duration of diet prior to BC diagnosis, or clinical staging of BC at diet 
initiation.  
Contrasting findings from the LF diet intervention, weight loss by ICR and CCR 
provided robust anticancer effects that were associated with enhanced immune 
signaling within the tumor microenvironment. Tumors from mice placed on CCR and 
ICR interventions exhibited enrichment for two immune-related gene sets (i.e. 
inflammatory response and allograft rejection) compared with control mice, indicating 
reversion of DIO-associated tumor immunosuppression as well as heightened tumoral 
immune signaling compared with control mice that had never been obese. There was a 
significant overlap in leading edge genes that contributed to the enrichment of CCR and 
ICR, compared with control, demonstrating that both diets exert similar transcriptional 
changes within the tumor microenvironment.  
Existing literature suggests that ICR performs similar to CCR in reducing 
systemic BC risk factors (e.g. IGF-1 and leptin) and inhibiting mammary 
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tumorigenesis171. Ours is the first study to directly compare the effect of these two 
interventions within the tumor microenvironment. Leading edge genes that were 
commonly enriched in CCR and ICR tumors included transcripts relating to CD3 T cell 
receptor (i.e. Cd3D and Cd247), downstream TCR signaling molecules (i.e. Itk, Lck, and 
Zap70), and cytotoxic effector molecules (e.g. Prf1, Gzma, and Gzmb), indicative of 
increased T cell activation and antitumor immune function. These findings demonstrate 
that CCR and ICR provide similar benefit in reducing tumor growth and enhancing 
antitumor immune responses, at least in preclinical studies. The prospect of two 
different dietary approaches that provide the same beneficial effects would provide 
patients with the opportunity to choose an intervention that best fits with their lifestyle 
and dietary preferences. 
Enhanced immune signaling in tumors from CCR and ICR mice, compared with 
control, was associated with a significant reduction in mammary tumor growth 
compared with DIO as well as control mice that had never been obese. Interestingly, 
CCR and ICR mice did not differ in body weight compared with young control mice at 
tumor transplant (data not shown; Bowers, et al, Unpublished). This suggests that the 
effects of CCR and ICR on tumor growth and enhanced tumor immune signaling are not 
solely due to decreased body weight. Other intermittent fasting regimens have been 
shown to improve antitumor immune surveillance without producing sustained weight 
loss. One example is short term starvation regimens that provide only water for up to 48 
hours and produce short-term weight loss that is quickly regained upon refeeding. Two 
cycles of fasting in lean mice bearing 4T1 tumors decreased tumor growth and 
increased efficacy of a chemotherapeutic agent173. This study did not investigate the 
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effects on the tumor immune microenvironment.  However, a subsequent publication by 
the research group demonstrated that a fasting-mimicking diet, that involves 4 day 
cycles of very low caloric intake every two weeks and again provides short-term yet 
unsustain weight loss174, enhanced CD8 T cell recruitment to and decreased regulatory 
T cell abundance within the mammary tumor bed following treatment with 
chemotherapeutic agent doxorubicin127. It is unknown if implementation of calorie 
restrictive interventions without substantial weight loss in obese subjects would provide 
the same anticancer effects. Further, determination of mechanisms through which 
calorie restrictive interventions improve immune surveillance and inhibit tumor growth 
without substantial weight loss would be of particular interest for the treatment of cancer 
patients at risk of developing cancer cachexia.  
Finally, this is the first study to demonstrate that the beneficial effects of ICR on 
tumor progression and the tumor immune microenvironment are also provided to aged 
and aged obese mice. ICR intervention in young DIO, aged control, and aged DIO mice 
significantly reduced tumor mass, relative to their aged-matched and baseline diet-
matched comparator. The anticancer effects of ICR were associated with enriched 
immune signaling within the tumor microenvironment. These findings are significant 
because the majority of patients developing and receiving treatment for BC are of 
advanced age and patients with advanced age or obesity at diagnosis experience 
poorer prognoses169,170. However, the feasibility and safety of ICR in short- or long-term 
remains to be determined in elderly individuals with or without obesity. 
This project has several strengths and limitations. Both preclinical models 
incorporate elements that increase translation to human BC. First, we utilized E0771 
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mammary carcinoma cell lines that model basal-like BC, a subtype associated with 
worse prognosis in humans9,11, and transplanted them orthotopically into the mammary 
fat pad. Second, the dietary interventions tested are clinically relevant, modeled after 
regimens currently under investigation in human clinical trials119,172,175,176. Third, we 
incorporate advanced age and obesity as variables to more accurately reflect the 
human populations at higher risk of developing and dying from BC14,169,170. Limitations 
include the inherent biological differences that exist between mice and humans. Future 
studies will need to test the translation of these findings to aged and obese humans with 
BC. Additionally, all of the immunological changes discussed herein are derived from 
bulk gene expression analysis; analyses are underway to determine whether these 
transcriptional alterations correlate with changes in intratumoral immune cell abundance 
via IHC. While these additional experiments will provide knowledge on immune cell 
infiltration, more work is needed to determined differences in immune cell phenotypes 
within the tumor microenvironment. To more robustly interrogate the effects of 
advanced age and obesity on tumor infiltrating CD8 T cells in this study, we dissociated 
tumors extracted from young control, young DIO, aged control, and aged DIO mice at 
study endpoint and isolated CD8 T cells using magnetic beads. Unfortunately, flow 
cytometric analysis of our CD8 T cells isolates revealed that many did not reach our 
predefined purity threshold of 85%. Thus, we could not adequately assess the impact of 
advanced age, obesity, and the combination of advanced age and obesity on tumor 
infiltrating CD8 T cell populations via planned transcriptional analyses. Future studies 
should determine the differential effects of advanced age, obesity, and the combination 
of advanced age and obesity on tumor-infiltrating immune cell populations, using either 
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magnetic beads as outlined above or alternative approaches such as single-cell 
transcriptional analysis.  
 Given the disproportionate BC incidence and mortality rates experienced by 
patients with advanced age and obesity, it is imperative to determine interventions to 
effectively reduce risk in these patient populations. One aspect of tumor biology that is 
associated with worse prognosis and therapeutic resistance is tumor 
immunosuppression.  We previously demonstrated that advanced age and obesity drive 
mammary tumor growth, in part, through tumor immunosuppression. Findings from this 
work demonstrates that calorie restriction interventions, but not a LF diet intervention, 
reverses obesity-associated tumor immunosuppression and diminishes tumor growth in 
formerly obese mice. Further, the anticancer effects of ICR extend to aged and aged 
obese mice. Due to the striking success of calorie restrictive interventions in enhancing 
antitumor immune signaling and diminishing tumor growth, implementation of these low-
cost and high accessibility interventions for BC prevention and treatment may provide 
far-reaching public health improvements. However, research must first determine the 













Figure 3.1 Weight loss by chronic calorie restriction (CCR) and intermittent 
calorie restriction (ICR) robustly alters expression of individual transcripts within 
the mammary tumor. A) Study schematic. B) Differentially expressed genes (DEGs) 
defined by fold-change cut off of >1.5 and FDR q-value <0.05. C-D) Volcano plots of 
DEGs and tables of select DEGs in CCR vs control (C) and ICR vs control (D). 
  
Gene Symbol Fold Change P-val FDR P-val
Prf1 2.33 0.0001 0.0118
Gzmb 2.12 0.0000599 0.009
Gzmc 3.88 0.0003 0.0216
Gzme 7.85 3.40E-06 0.0022
Gzmf 14.17 9.39E-07 0.001
Gzmg 14.63 0.0002 0.0166
Gzmd 26.38 6.12E-06 0.0026
Differentially Expressed Transcripts CCR vs Control
Gene Symbol Fold Change P-val FDR P-val
Ctla4 1.66 0.0006 0.0091
Havcr2 1.84 0.0013 0.0157
Cd83 1.77 0.0021 0.0212
Icos 1.67 0.0017 0.0183
Tnfrsf18 1.79 1.90E-03 0.0196




Figure 3.2 DIO tumors underrepresent immune-related gene sets. A-B) Hallmark 
gene sets underrepresented (A) and enriched (B) in mammary tumors from young DIO 
mice vs young control mice determined by gene set enrichment analysis (GSEA). 




Table 3.1 Hallmark gene set enrichment in mammary tumors from aged DIO mice 
vs aged control.  
 
 
DIO, diet-induced obese; LF, Low-fat; CCR, chronic calorie restriction; ICR, intermittent 
calorie restriction; NES, normalized enrichment score; FDR, false discovery rate. 
  
NES FDR q-val NES FDR q-val NES FDR q-val NES FDR q-val
HALLMARK_ALLOGRAFT_REJECTION -2.72 < 0.001 -1.65 0.030 1.77 0.017 1.86 0.001
HALLMARK_INTERFERON_ALPHA_RESPONSE -2.64 < 0.001 -1.89 0.003
HALLMARK_INTERFERON_GAMMA_RESPONSE -2.63 < 0.001 -1.96 0.002
HALLMARK_IL2_STAT5_SIGNALING -1.50 0.025
HALLMARK_IL6_JAK_STAT3_SIGNALING -1.80 0.001
HALLMARK_INFLAMMATORY_RESPONSE -1.72 0.002 1.61 0.049 1.56 0.035
HALLMARK_ADIPOGENESIS 2.15 < 0.001 2.03 < 0.001 1.93 < 0.001
HALLMARK_ANGIOGENESIS 1.57 0.023 1.62 0.033
HALLMARK_MYOGENESIS -2.47 < 0.001 -2.74 < 0.001 -2.77 < 0.001 -3.28 < 0.001
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 1.63 0.019 -2.16 < 0.001 -2.18 < 0.001
HALLMARK_FATTY_ACID_METABOLISM 1.69 0.015 1.59 0.025
HALLMARK_XENOBIOTIC_METABOLISM 1.56 0.023 1.62 0.025
HALLMARK_GLYCOLYSIS 1.61 0.018
HALLMARK_E2F_TARGETS -2.13 < 0.001
HALLMARK_G2M_CHECKPOINT -1.90 < 0.001
HALLMARK_MYC_TARGETS_V1 -1.75 0.002
HALLMARK_ANDROGEN_RESPONSE 1.44 0.037 1.53 0.038
HALLMARK_ESTROGEN_RESPONSE_EARLY 1.53 0.023
HALLMARK_COAGULATION 1.48 0.032 1.67 0.027
HALLMARK_HYPOXIA 1.53 0.025
HALLMARK_UV_RESPONSE_DN 1.75 0.008






























































Figure 3.3 Weight loss by CCR and ICR, not LF diet, reverse DIO-related tumor 
immunosuppression. A-B) Venn diagrams of Hallmark gene sets commonly 
underrepresented (A) and enriched (B) in mammary tumors from DIO, LF, CCR, and 
ICR mice vs control. C) Leading edge analysis (LEA) of commonly underrepresented 
immune-related Hallmark gene sets in DIO vs control and LF vs control. D) Heat map of 
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select leading edge genes. E) Leading edge analysis (LEA) of commonly enriched 
immune-related Hallmark gene sets in CCR vs control and ICR vs control. F) Heat map 
of select leading edge genes. Significantly enriched gene sets defined as FDR q-val 
<0.05. Significance in overlap of leading edge genes analyzed using hypergeometric 




Table 3.2 Leading edge genes commonly underrepresented in DIO and LF vs 
control and enriched in CCR and ICR vs control. 
 
  
Apol6 Herc6 Parp14 C3ar1 Ncr1
Arl4a Hla-dma Parp9 C5ar1 Olr1
Batf2 Hla-dmb Prf1 Calcrl P2rx4
Bcat1 Icam1 Prkcb Ccl22 Pik3r5
Casp1 Ifi44 Psmb10 Ccr1 Prf1
Ccl11 Ifih1 Psmb9 Ccr2 Ptpre
Ccl4 Ifit2 Psme2 Ccr7 Rasgrp1
Ccl5 Ifit3 Ptpn6 Cd14 Sell
Ccr2 Ifng Ptprc Cd1d Sema4d
Ccr5 Igsf6 Rpl3l Cd2 Spi1
Ccrl2 Il10 Rtp4 Cd247 St8sia4
Cd2 Il10ra Samd9l Cd28 Stat4
Cd274 Il12a Sectm1 Cd3d Tlr2
Cd3d Il12rb1 Serping1 Cd55 Tnfsf9
Cd3g Il15 Slamf7 Cd70 Vip
Cd69 Il15ra Socs1 Cd86 Was
Cd74 Il16 Sp110 Cfp Zap70
Cd86 Il18bp Spi1 Clec5a
Cd8a Il1b Sppl2a Cmklr1
Cmpk2 Il2rb Stat1 Faslg
Crtam Il7 Stat2 Fgr
Ctss Irf1 Stat4 Gpr183
Cxcl11 Irf5 Tap1 Gzma
Cxcl9 Irf7 Tap2 Gzmb
Ddx60 Isg20 Tent5a Hcls1
Dhx58 Isoc1 Thy1 Ifnar1
Eif2ak2 Itgal Tlr1 Igsf6
Eif4e3 Itgb2 Tnf Il10ra
Epsti1 Jak2 Tnfsf10 Il2ra
Fas Klrd1 Trafd1 Il2rb
Faslg Klrk1 Trim14 Il4
Fcgr1a Lcp2 Trim21 Il7r
Fgl2 Ly86 Trim5 Itgb2
Fgr Mx1 Ube2l6 Itk
Fpr1 Nlrc5 Vamp5 Kcna3
Fyb1 Nme1 Vcam1 Klrd1
Gbp2 Nmi Xaf1 Lck
Gbp6 Nod1 Xcl1 Lcp2
Gpr18 Oas2 Zbp1 Mefv
Gpr65 Oas3 Msr1
Gzmb P2ry14 Ncf4
Genes Commonly Underrepresented 
in DIO vs Control and LF vs Control
Genes Commonly Enriched in CCR 




Figure 3.4 Implementation of ICR in obese, aged, and aged obese mice reduces 
body weight to levels at or below that observed in young control mice. A) Study 
schematic. B) Body weight, C) % body fat mass, and D) % lean mass measured prior to 
ICR implementation. E) Average energy intake (kcal consumed per day) and F) average 
energy intake relative to average body weight measured over a three week period prior 
to ICR implementation. G) Body weight at 9 weeks following randomization of mice to 
either remain on diet ad libitum or switch to ICR intervention. Additional data 
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Figure 3.5 ICR reduces tumor growth in obese, aged, and aged obese mice. A) In 
vivo tumor growth monitored by caliper measurement of tumor length (L), the greatest 
diameter, and width (W), the diameter perpendicular to the L, and the equation V=L x 
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Table 3.3 Hallmark gene set enrichment in mammary tumors from young DIO, 
aged control, and aged DIO compared with young control. 
 
 
DIO, diet-induced obese; NES, normalized enrichment score; FDR, false discovery rate. 
  
NES FDR q-val NES FDR q-val NES FDR q-val
HALLMARK_INTERFERON_GAMMA_RESPONSE -2.09 < 0.001 -2.21 < 0.001 -1.55 0.012
HALLMARK_ALLOGRAFT_REJECTION -2.02 < 0.001 -2.35 < 0.001 -1.61 0.008
HALLMARK_INTERFERON_ALPHA_RESPONSE -1.71 0.009 -2.10 < 0.001 -2.02 < 0.001
HALLMARK_IL6_JAK_STAT3_SIGNALING -1.50 0.045 -1.81 0.001
HALLMARK_IL2_STAT5_SIGNALING -1.79 0.001
HALLMARK_INFLAMMATORY_RESPONSE -1.59 0.013
HALLMARK_MYOGENESIS -1.71 0.007 1.58 0.042
HALLMARK_ADIPOGENESIS -1.52 0.047 1.62 0.042
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 1.78 0.009



































Figure 3.6 Weight loss by ICR enhances immune signaling in young DIO, aged 
control, and aged DIO mice. A) Hallmark gene sets underrepresented in mammary 
tumors of young DIO, aged control, and aged DIO vs young control mice determined 
following gene set enrichment analysis (GSEA). B) Hallmark gene sets enriched in 
mammary tumors from Aged DIO vs aged control and young DIO determined via GSEA. 
C) Hallmark gene sets underrepresented in mammary tumors from ad libitum-fed young 
control, young DIO, aged control, and aged DIO mice relative to their respective ICR 
comparator. Significantly enriched gene sets defined as FDR q-val <0.05. Asterisks 




Table 3.4 Hallmark gene set enrichment in mammary tumors from aged DIO vs 
young DIO and aged DIO vs aged control. 
 
 
DIO, diet-induced obese; NES, normalized enrichment score; FDR, false discovery rate. 
  
NES FDR q-val NES FDR q-val
HALLMARK_ALLOGRAFT_REJECTION 1.47 0.029 2.20 < 0.001
HALLMARK_INFLAMMATORY_RESPONSE 1.44 0.039 1.62 0.008
HALLMARK_INTERFERON_GAMMA_RESPONSE 1.94 < 0.001
HALLMARK_IL6_JAK_STAT3_SIGNALING 1.72 0.004
HALLMARK_IL2_STAT5_SIGNALING 1.71 0.004
HALLMARK_MYOGENESIS 2.13 < 0.001 1.67 0.005
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 2.04 < 0.001 1.67 0.005
HALLMARK_ANGIOGENESIS 1.73 0.001 1.68 0.006
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Table 3.5 Hallmark gene set enrichment in mammary tumors from young control, 




DIO, diet-induced obese; ICR, intermittent calorie restriction; NES, normalized 
enrichment score; FDR, false discovery rate.
NES FDR q-val NES FDR q-val NES FDR q-val
HALLMARK_ALLOGRAFT_REJECTION 2.34 < 0.001 2.67 < 0.001 1.81 < 0.001
HALLMARK_IL6_JAK_STAT3_SIGNALING 2.07 < 0.001 2.11 < 0.001
HALLMARK_INFLAMMATORY_RESPONSE 1.90 < 0.001 2.02 < 0.001
HALLMARK_INTERFERON_ALPHA_RESPONSE 1.95 < 0.001 2.24 < 0.001 2.11 < 0.001
HALLMARK_INTERFERON_GAMMA_RESPONSE 2.27 < 0.001 2.33 < 0.001 1.57 0.026
HALLMARK_IL2_STAT5_SIGNALING 1.85 < 0.001 1.93 < 0.001
HALLMARK_COMPLEMENT 1.65 0.004 1.51 0.037
HALLMARK_ADIPOGENESIS 2.19 < 0.001
HALLMARK_ANGIOGENESIS 1.62 0.005
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION -1.78 0.002
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CHAPTER 4. SYNTHESIS 
Contributions to the Field 
 This dissertation work sought to determine if advanced age promotes mammary 
tumor growth and, following our observation that it did, investigate if shared 
mechanisms drive advanced age- and obesity-associated mammary tumor burden, 
specifically mammary adipose inflammation and tumor immunosuppression. We 
subsequently tested the efficacy of various dietary interventions in reversing obesity- 
and advanced age-related acceleration of mammary tumor growth and tumor 
immunosuppression. 
In Chapter 2 we demonstrate for the first time that advanced age increases 
mammary tumor growth, using two murine models of breast cancer (BC), and that diet-
induced obesity (DIO) in aged mice further exacerbates mammary tumor burden. 
Obesity is known to cultivate an inflamed adipose microenvironment rich in 
proinflammatory mediators that support tumor progression and immunosuppressive 
molecules and immune cell types that promote tumor immune evasion68.  We found that 
similar to DIO, advanced age induced transcriptional alterations within the tumor-
adjacent mammary fat pad indicative of increased inflammatory- and immune-related 
signaling. Enriched transcripts included those relating to IL-6/JAK/STAT3 signaling, 
which stimulates immunosuppression through multiple mechanism including the 
expansion of myeloid derived suppressor cells and attenuation of T cell responses161,162. 
Thus, advanced age and obesity promote inflammatory and immunosuppressive 
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signaling within the tumor-adjacent mammary fat pad which could suppress antitumor 
immunity.  
Tumor transcriptional analyses reveal that advanced age and obesity converge 
on suppression of immune-related transcripts including those relating to T cell receptor 
signaling/activation (e.g. Cd3e, Cd8b1, Ifng) and cytotoxic effector functions (e.g. Prf1, 
Gzma) in aged control and young DIO mice, compared with young controls. Coherently, 
IHC analysis showed reduced abundance of T cells and cells positive for CD8, a co-
receptor found on cytotoxic CD8 T cells, in mammary tumors from aged control and 
young DIO mice, relative to young controls. Thus, advanced age and obesity reduces 
CD8 T cell tumor immune surveillance. Finally, antibody depletion of CD8 T cells 
enhances mammary tumor growth, compared with isotype controls, signifying that CD8 
T cell mediated antitumor immunity is critical determinant for tumor growth in this model. 
Taken together, these findings indicate reduction in CD8 T cell immune surveillance as 
a significant contributor to advanced age and obesity-associated acceleration of 
mammary tumor growth. 
Contrasting advanced age and obesity, dietary caloric restriction exerts potent 
anticancer effects and improves immune cell function95,107-109,127,171. Therefore, we 
sought to determine if dietary interventions that reduce caloric intake attenuate tumor 
immunosuppression in aged, obese, and aged obese mice. In Chapter 3, we found that 
weight loss by chronic calorie restriction (CCR) or intermittent calorie restriction (ICR) 
decreases tumor growth, compared with DIO mice that did not receive a weight loss 
intervention. Further, weight loss by CCR or ICR intervention reduces tumor burden 
below levels observed in control mice that were never obese. In contrast, weight loss by 
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a low-fat (LF) diet provided ad libitum does not result in differential tumor growth 
compared with DIO mice indicating that weight loss by LF diet is insufficient in reverse 
obesity-associated acceleration of mammary tumor growth. Again, we found that DIO 
suppresses immune-related transcriptional signatures within the tumor 
microenvironment. In addition to diminishing tumor growth, CCR and ICR interventions 
enhance immune-related transcriptional signatures within the mammary tumor, 
enriching for genes relating to TCR signaling (e.g. Cd3d, Itk, and Lck) and T cell effector 
function (e.g. Prf1, Gzma, and Gzmb), relative to controls. In opposition, LF diet 
intervention results in underrepresentation for immune-related signatures. Tumors from 
LF and DIO mice convergently underrepresent transcripts relating to T cell recruitment 
(e.g. Ccl5, Cxcl9, and Cxcl11), T cell receptor signaling (e.g. Cd3d, Cd8), and T cell 
effector function (e.g. Prf1 and Gzmb). Thus, only calorie restrictive interventions 
reverse obesity-associated acceleration of mammary tumor growth and suppression of 
immune-related transcription. In addition to young DIO mice, ICR proved effective in 
aged control and aged DIO mice. Weight loss by ICR diminishes tumor growth in aged, 
obese, and aged obese mice and enhances immune-related transcription within the 
mammary tumor microenvironment. 
The Problem: Lost in Translation to Patients 
Drug development research faces major challenges in translation of basic 
science findings to the clinic. It is estimated that only 0.01% of basic science projects 
pass through clinical trials and receive FDA drug approval177. Major causes of this 
failure are lack of therapeutic effectiveness or adverse patient responses that were not 
predicted in preclinical models177. In humans, advanced age and obesity are major risk 
factors for BC development and mortality14,24. However, preclinical research aimed at 
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understanding mechanisms of therapeutic resistance and identifying new therapeutic 
targets for BC patients often utilize young, lean mice. Findings from this dissertation 
project indicate that advanced age- and obesity-related acceleration of mammary tumor 
growth is associated with enhanced inflammatory and immunosuppressive signaling in 
the mammary adipose and tumor immunosuppression, compared with young 
normoweight mice, in preclinical BC models. Thus, utilization of young, lean mice in 
development of mechanistic explanations and treatment strategies fails to replicate 
human clinical BC treatment conditions with regard to advanced age- and obesity-
related chronic inflammatory signaling and immune dysfunction.  
This section discusses preclinical study design and methodology that provide 
more accurate modeling of the aged and obese environment in which cancer is more 
likely to develop and progress and may ultimately increase translation to human cancer. 
Specifically, I will discuss: 1) incorporation of advanced age and obesity in preclinical 
cancer studies; 2) alternative approaches to model age-related cancer progression; and 
3) modeling the human immune system in preclinical models.  
Incorporation of advanced age and obesity in preclinical cancer studies 
Akin to this dissertation work, others have utilized aged or obese mice to study 
human cancer and they have been able to draw parallels between their preclinical 
findings and clinical observations. One preclinical study demonstrated that obesity 
results in PD-1-mediated T cell dysfunction across multiple species (mice, rhesus 
macaques monkeys, and humans)78. Further treatment of obese, melanoma-bearing 
mice  with an immunotherapeutic agent that targeted PD-1, diminished tumor 
progression compared with obese, isotype treated controls78. In contrast, treatment with 
anti-PD-1 did not elicit differential tumor growth in lean, melanoma bearing mice78. 
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Clinical observations are in agreement with these preclinical findings demonstrating that 
obesity is correlated with improved outcomes following anti-PD-1 treatment 78,178,179. 
Similarly, in both preclinical and clinical studies advanced age is associated with 
improved response to anti-PD-1 therapy180. These studies demonstrate the potential for 
findings from preclinical studies, in which aged and obese mice are utilized, to predict 
therapeutic response in patients with advanced aged and obesity. Not only have 
preclinical studies demonstrated advanced age- and obesity-associated differences in 
therapeutic efficacy, they have also indicated differential propensity for adverse 
therapeutic responses. For example, one study found that advanced age resulted in 
severe toxicity after treatment of mice with anti-CD40/IL-2 immunotherapy181. Thus, 
incorporation of advanced age and obesity as variables in preclinical studies would 
inform preclinical to clinical translation efforts on therapeutic efficacy and potential 
toxicities that may be experienced in older or obese patients.  
Therapeutic agents utilized in the studies described above are immunotherapies, 
or agents that are used to stimulate the host’s immune response to recognize and 
destroy cancer cells. Over the past 10 years, there has been growing interest in use of 
immunotherapy for anti-cancer treatment182. Immunotherapeutic agents confer durable 
responses that significantly improve long-term survival across a broad range of cancers, 
including metastatic melanoma, renal cell carcinoma, and more recently triple negative 
BC80,182. However, not all patients respond to immunotherapy and some develop 
immune-related adverse events that can result in patient death182. Given, known 
immune aberrations with advanced age and obesity, interrogating the effects of 
advanced age and obesity in preclinical immunotherapy trials will aid in establishing a 
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more complete picture of risks and/or benefits that may translate to patients in clinical 
trials. 
In conclusion, preclinical study design should investigate the differential effects of 
advanced age and obesity on BC biology and therapy to more closely model the human 
sub-population at greater risk of developing and dying from the disease. Incorporation of 
advanced age and obesity at the preclinical stage would aid in the identification of novel 
agents to improve BC outcomes in aged and obese subjects and could inform 
researchers of potential toxicity risks. 
Alternative approaches to model age-related cancer progression  
In contrast to the link between obesity and BC progression, relatively few studies 
have investigated the effects of advanced age on BC progression. Similar to methods 
used in this dissertation project, the majority of these studies have tested the effects of 
advanced age on BC by transplanting fully transformed, genetically identical tumor cells 
into the mammary adipose of aged mice. This study design tests the impact of 
advanced aged on mammary tumor growth; however, it does not capture the effects 
that advanced age may have on mammary tumor development and progression. Below, 
we discuss methodology that could be utilized in future research to examine the impact 
of advanced age on mammary tumor development and progression.  
 To mimic the clinical progression of BC, clinically relevant genomic alterations, 
such as oncogenes that are over expressed in human BC (e.g. ErbB2, MYC, PIK3CA), 
could be packed into viral vectors and introduced into the mammary epithelial cells of 
aged and young mice by intraductal injection183,184. Alternatively, aged and young mice 
could be treated with chemical carcinogens that invoke the initiation and progression of 
mammary tumors, such as medroxyprogesterone acetate or 
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dimethylbenz(a)anthracene185,186. These models allow investigation of cancer 
progression from early preneoplastic to metastatic lesions which enables researchers to 
determine the effects of age on mammary tumor incidence and progression as well as 
tumor-intrinsic features (e.g. tumor mutational landscape or epigenetics) 
 Currently, there is limited preclinical work investigating the effects of advanced 
age on BC. Moreover, most of these existing studies utilize tumor transplantation 
models which test the effects of advanced age on growth of fully developed tumor cells 
and does not address tumor development. Future work should expand beyond these 
foundational studies and utilize preclinical models that test the effects of advanced age 
on the developmental progression of BC.  
Modeling the human immune system preclinically  
It is important to consider biological differences that exist between mice and 
humans. Specific to this dissertation work, in which advanced age and obesity-related 
tumor progression was associated with tumor immunosuppression, differences between 
the human and mouse immune system will have to be acknowledge. For example, mice 
have a greater abundance of circulating lymphocytes (75-90% of circulating immune 
cells) compared with humans (30-50% of circulating immune cells187). In addition to 
differential abundance, there is differential biology between mouse and human T 
lymphocytes with close to 100% of mice CD4 and CD8 T cells express the costimulatory 
receptor CD28 whereas only 80% of human CD4 and 50% of human CD8 T cells 
express CD28187. Further, transcriptional studies have demonstrated convergence as 
well as divergence in the mouse and human immune response152. 
To address the apparent differences across species, humanized mouse models 
have been developed to more accurately reflect of human immune responses and help 
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address the apparent differences between species188. These models involve engrafting 
immunodeficient mice with components of the human immune system such as 
peripheral blood leukocytes, human CD34+ hematopoietic stem cells, or a combination 
of human fetal liver, thymus, and hematopoietic stem cells188.  Models in which 
hematopoietic stem cells are transplanted into immunodeficient mice supports 
engraftment of the complete human immune system making it an attractive model for 
studying the effects of the aged immune system on BC biology and progression188.  To 
interrogate the aged human immune response to BC, studies could reconstitute mice 
with hematopoietic stem cells from aged and young donors and then challenge mice 
with transplantation of either human-derived mammary carcinoma cell culture lines or 
patient-derived xenografts. However, these models do not come without limitations. For 
example, in the hematopoietic stem cell engraftment model mice T cells are educated in 
the mouse thymus, which lacks human-specific factors involved in T cell development 
and thus does not fully replicate human T cell development188. Given our findings, of 
age-related tumor immunosuppression in preclinical models of BC it would be beneficial 
to utilize humanized mouse models to test the translation of these findings to the aged 
human immune system.  
Beneficial Effects of Calorie Restriction Interventions in Cancer Treatment 
In our study, calorie restriction interventions were implemented prior to BC 
inoculation and thus tested the efficacy of these dietary patterns in preventing advanced 
age- and obesity-related acceleration of BC growth and tumor immunosuppression.  
While our study and others have demonstrated profound cancer preventative effects of 
calorie restriction interventions, long-term adherence to calorie restriction diets is a 
significant challenge to some patients and motivation to sustain healthy lifestyle 
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changes may be lower prior to disease diagnosis. Rather than focusing on cancer 
preventative effect of calorie restriction, recent attention has focused on calorie 
restriction interventions as adjuvant therapy with or without traditional chemotherapy or 
immunotherapeutic agents.  
Dr. Valter Longo and collaborators have extensively interrogated the role dietary 
restriction on tumor progression and therapeutic response. Their initial focus was on 
periodic fasting, also referred to as short-term starvation, in which tumor-bearing mice 
were fasted (provided only water) for 48-60 hours followed by ad libitum feeding173. 
Cycles of periodic fasting in tumor-bearing mice diminished tumor growth and improved 
response to chemotherapy across multiple preclinical tumor models including models of 
BC173. Follow-up clinical cancer studies have demonstrated periodic fasting while 
actively undergoing cancer treatment decreases adverse effects of chemotherapy189. In 
one clinical study, ten cancer patients of varying cancer types (four breast, two prostate, 
one ovarian, one uterine, one small cell carcinoma of the lung, and one esophageal 
adenocarcinoma) voluntarily fasted prior to (48-140 hours) or following (5-56 hours) 
chemotherapy treatment189. Compared with non-restricted control subjects, fasting 
reduced chemotherapy-induced side effects including fatigue, weakness and 
gastrointestinal side effects189. In another study, short term periodic fasting among 
stage II/III breast cancer patients was not only well tolerated amongst study participants 
but also, reduced signs of hematological toxicity and stimulated faster recovery from 
DNA damage in normal host peripheral blood mononuclear cells.190  
To mitigate perceived risks of implementing periodic fasting in cancer patients, 
the Longo laboratory has developed a fasting-mimicking dietary regimen that involves 
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very low calorie consumption (between 300 and 1,100 kcal per day) over 1-5 
consecutive days followed by a regular diet. The fasting mimicking diet provides many 
of the same benefits of periodic fasting with better patient compliance174,191. A recent 
clinical trial tested the translation of the fasting-mimicking diet into BC patients. In the 
multicenter phase 2 DIRECT trial, BC patients randomly assigned onto the fasting-
mimicking diet were more likely to experience radiological complete or partial response 
following chemotherapy treatment and were no more likely to experience adverse 
events, compared with patients on a regular diet192. Further, circulating T cells from 
patients on the fasting-mimicking diet exhibited reduced γ-H2AX intensity, a marker of 
DNA double-strand breaks,  following chemotherapy treatment, relative to patients on a 
regular diet, indicating protection from chemotherapy-induced DNA damage192.  
For patients which weight loss and development of cachexia is a concern, 
pharmacological agents that modulate calorie restriction related metabolic pathway may 
provide the same therapeutic benefit as calorie restrictive interventions without 
significantly altering dietary intake. One example is Hydroxycitrate, an inhibitor of ATP 
citrate lyase that is involved in fatty acid synthesis. Hydroxycitrate treatment in 
normoweight mice resulted in greater efficacy of the chemotherapeutic agent 
mitoxantrone193. Enhanced antitumor effects with Hydroxycitrate treatment were 
dependent on CD8 T cells and associated with reduced tumor-infiltrating T regulatory 
cells193. Treatment with metformin, which exerts multiple metabolic actions including 
activation of AMPK (which is observed with CCR and ICR), inhibited tumor cell oxygen 
consumption and reduces intratumoral hypoxia providing a more favorable environment 
for T cells to infiltrate following treatment with anti-PD1 immunotherapy194.  
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This dissertation project demonstrates the cancer preventative capacity of long-
term calorie restriction interventions in aged, obese, and aged obese mice. Results from 
the preclinical and clinical studies outlined above show that short-term calorie restriction 
interventions and pharmacological mimetics can provide significant therapeutic benefit 
when implemented in tumor bearing subjects and result in diminished tumor growth, 
improved therapeutic efficacy, and reduced therapeutic toxicity. However, whether 
calorie restriction interventions would provide similar benefit as adjuvant therapy in aged 
and/or obese subjects with cancer has yet to be determined.  Future work should 
establish whether calorie restriction interventions safely and effectively provide 
therapeutic benefit to obese and/or advanced aged subjects with cancer. 
Strengths and Limitations 
This dissertation work has many strengths in its experimental design, allowing 
the potential to draw relevant conclusions. First, we incorporated advanced age and 
obesity as variables in order to more closely model the human populations with the 
greatest risk of developing and dying from BC. Second, we chose clinically relevant 
dietary interventions that are utilized in clinical studies and have demonstrated 
anticancer potential in either preclinical and/or clinical studies. Finally, we tested the 
reproducibility of major study findings across multiple experiments and preclinical BC 
models. In Chapter 2, the impacts of advanced age and obesity on promotion of BC 
growth and tumor immunosuppression were observed across two independent 
experiments in which mice were challenged with different BC cell lines modeling two 
distinct human BC subtypes. In Chapter 3, we demonstrated that the beneficial effects 




 This work also has several limitations. First, we utilized preclinical models to 
investigate human diseases and as described above inherent differences exists across 
the two species. Future studies should determine whether our findings translate to 
human BC, particularly to basal-like and claudin-low BC subtypes modeled in our 
preclinical experiments. In addition, our utilization of bulk tumor gene expression data to 
probe alterations within the tumor microenvironment limits our ability to assess 
alterations to specific cell populations within the tumor. To address these concerns, IHC 
is utilized to probe differential immune cell abundance. Future studies should determine 
the differential effects of advanced age and obesity the characteristics of tumor-
infiltrating immune cell populations, using single cell RNAseq or NanoString spatial 
profiling.  
Concluding Remarks 
Advanced age and obesity are characteristic of the majority of patients with BC, 
yet preclinical investigations into BC mechanisms and drug development largely utilize 
young, lean mice. This dissertation demonstrates that the young, lean tumor 
microenvironment is not equivalent to the aged and obese tumor microenvironment. 
Advanced age and obesity induce tumor immunosuppression which is associated with 
enhanced tumor burden. Future preclinical BC studies may benefit from incorporating 
advanced age and obesity as variables to increase the translation of findings into 
human populations that are at higher risk of developing and dying from BC. In addition, 
advanced age- and obesity-related tumor immunosuppression and acceleration of 
tumor growth are effectively reversed following implementation of an ICR dietary 
intervention. Implementation of low-cost dietary interventions for cancer prevention and 
treatment would have far reaching public health impacts; however, more work is needed 
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to determine feasibility of these interventions in BC patients that are aged, obese, or 
aged and obese. This work specifically studied adipose inflammation, breast anti-tumor 
immunity, and CR as an immune-modulating intervention for BC. Future BC clinical 
work may benefit from incorporating these findings. In addition, future preclinical work 











A) Body weight of young and aged cohort upon arrival, prior to randomization to control 
or DIO diet. B) Weekly weight change and C) rate of weight change on baseline control 
or DIO diets. D) Total body fat and E) lean mass measured prior to randomization to 
either remain on respective diets ad libitum or switch to intermittent calorie restriction 
regimen. F) Average daily intake measured over a three week period prior to 
randomization onto either intervention arm. G) Percent weight change and H) rate of 
weight change in mice that remained on respective diets provided ad libitum. I) Percent 
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